

# CURRICULUM VITAE

## RYAN D. GENTZLER, M.D., M.S.

### I. PERSONAL DATA

**Office:** Division of Hematology/Oncology  
University of Virginia School of Medicine  
PO Box 800716  
Charlottesville, VA 22901  
(434) 243-6797  
[rg2uc@virginia.edu](mailto:rg2uc@virginia.edu)

**Citizenship:** USA  
**Date of Birth:** April 22, 1982  
**Place of Birth:** Hanover, PA

### II. EDUCATION

M.S. Pharmacology	Thomas Jefferson University Philadelphia, PA	2011
M.D.	Temple University Philadelphia, PA	2008
B.S. Biology	Davidson College Davidson, NC	2004

### III. POST-GRADUATE EDUCATION

Leadership in Academic Matters (LAM) Faculty Development Course	University of Virginia Charlottesville, VA	Spring 2022
Methods in Clinical Cancer Research Workshop	ASCO/AACR Vail, CO	July 2013
Fellowship Hematology/Oncology	Northwestern University Chicago, IL	2011–2014
Internship/Residency Internal Medicine	Thomas Jefferson University Hospital Philadelphia, PA	2008–2011

### IV. ACADEMIC APPOINTMENTS

Associate Professor Medicine	University of Virginia Charlottesville, VA	July 2020
Assistant Professor Medicine	University of Virginia Charlottesville, VA	August 2014

## V. CERTIFICATION AND LICENSURE

### A. Certification

Medical Oncology	2014	322477
Internal Medicine	2011	322477

### B. Licensure

Virginia	2014	Permanent 0101256284
----------	------	----------------------

## VI. HONORS AND AWARDS

<u>Recognition of Outstanding Patient Experience</u> UVA Health System <i>99<sup>th</sup> Percentile for outpatient clinic patient experience scores, FY2022</i>	2022
<u>Recognition of Outstanding Patient Experience</u> UVA Health System <i>99<sup>th</sup> Percentile for outpatient clinic patient experience scores, FY2021</i>	2021
<u>Recognition of Outstanding Patient Experience</u> UVA Health System <i>99<sup>th</sup> Percentile for outpatient clinic patient experience scores, FY2020</i>	2020
<u>Excellence in Research</u> Department of Medicine, UVA <i>The award recognizes success and contributions in furthering scientific discovery.</i>	2020
<u>Recognition of Outstanding Patient Experience</u> UVA Health System <i>99<sup>th</sup> Percentile for outpatient clinic patient experience scores, FY2019</i>	2019
<u>Recognition of Outstanding Patient Experience</u> UVA Health System <i>99<sup>th</sup> Percentile for outpatient clinic patient experience scores, FY2018</i>	2018
<u>Excellence in Clinical Care Award</u> Department of Medicine, UVA <i>Demonstrated outstanding productivity, a high level of patient satisfaction, development of new programs, or other areas of excellence.</i>	2018
<u>Compassionate Care Award</u> Northwestern University Women's Board <i>The award honors individuals who exemplify and serve as role models for their extraordinary service to oncology patients.</i>	2014
<u>Chief Fellow, Hematology/Oncology</u> Northwestern University	2013

Excellence in Teaching Award 2013  
 Dept. of Medicine, Northwestern University  
*Selected by faculty for a fellow who demonstrates commitment to education.*

NCCN Fellows Recognition Program Travel Award 2013  
*Awarded an educational grant to pay for travel and accommodations to attend the NCCN 18th Annual Conference in Hollywood, FL and participate in the NCCN Fellows Recognition Program.*

The Kowlessar Award for Excellence in General Medicine 2013  
 Thomas Jefferson University Hospital  
*For a resident who has demonstrated commitment to excellence in the practice of internal medicine, education of residents and medical students, and compassion for those who are suffering.*

Emmanuel M. Weinberger Award for Hematology/Oncology 2008  
 Temple University School of Medicine  
*For outstanding achievement in hematology/oncology during the fourth year of medical school.*

Raymond Joseph Harris Educational Fund Scholarship 2005–2008  
 Temple University School of Medicine  
*For academic excellence, community service, financial need and cumulative educational debt.*

**VII. PROFESSIONAL AFFILIATIONS (INCLUDING OFFICES HELD)**

<i>Journal of Clinical Oncology,</i>	Editor	2024–Present
<i>ASCO Meeting Abstracts</i>	Associate Editor	2021–2023
Thoracic Clinical Trials Working Group, Hoosier Cancer Research Network (HCRN)	Co-Chair	2020–Present
NCI Experimental Therapeutics Clinical Trials Network (ETCTN)	Grant PI, UVA Site PI	2020–Present
Cancer Therapeutics Program, UVA Cancer Center		2014–Present
Hoosier Cancer Research Network (HCRN)		2014–Present
Eastern Cooperative Oncology Group (ECOG-ACRIN)		2014–Present
International Association for the Study of Lung Cancer (IASLC)		2012–Present
American Society of Clinical Oncology (ASCO)		2011–Present

**VIII. RESEARCH ACTIVITIES**

**A. Areas of Research Interest**

My research is centered around the development of novel therapies for patients with lung cancer through clinical investigation. I have experience developing and running investigator-initiated trials and treating patients on early and late-phase clinical trials. My interests have been novel therapeutic strategies involving immunotherapy

approaches as well as targeted therapy approaches, such as targeting EGFR mutations.

## **B. Current Projects**

1. Phase II study of adagrasib plus SRS for KRAS-mutated NSCLC with active brain metastases
  - a. Project Number: HRCN LUN23-618
  - b. Name of PD/PI: Gentzler, Ryan (Role: Multi-institutional PI)
  - c. Source of Support: Mirati/BMS
  - d. Primary Place of Performance; University of Virginia
  - e. Project Start and End Date: 5/1/23–
  - f. Total Award Amount:
  - g. Person Months: 0.36
  
2. A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
  - a. Project Number: PUMA-ALI4201
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Puma Biotechnology, Inc
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 11/13/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
3. Phase 3, Open-Label, Randomized, DZD9008 versus Platinum-Based Doublet Chemotherapy, 1st line
  - a. Project Number: DZ2022E0005
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Dizal Pharmaceuticals
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 7/26/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
4. A phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer
  - a. Project Number: HCRN-LUN21-497
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Hoosier Cancer Research Network
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 5/24/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
5. A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 As Monotherapy In Patients With Locally Advanced Or Metastatic Solid Tumors
  - a. Project Number: SPK-101-JG, UVA IRB-HSR 220309
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Chugai

- d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 4/14/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
6. PRAGMATICA - LUNG: A Prospective Randomized Study of ramucirumab (LY3009806; NSC 749128) plus pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
  - a. Project Number: S2302
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: NCI, SWOG
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date 3/30/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
7. Sotorasib Activity in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101)
  - a. Project Number: 20190135 (CodeBreak101)
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Amgen
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 2/2/23–
  - f. Total Award Amount:
  - g. Person Months: 0.12
8. Characterizing outcomes of first-line systemic treatment of metastatic/locally recurrent NSCLC following prior treatment with chemoradiation and durvalumab
  - a. Project Number: UVA IRB-HSR 24081
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: None
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 8/23/22–
9. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
  - a. Project Number MK7684A-007, UVA IRB-HSR 210551
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Merck
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 6/17/22–
  - f. Total Award Amount:
  - g. Person Months: 0.12
10. A Phase III, Double-Blind, Placebo-Controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer

- a. Project Number: PACIFIC-9, UVA IRB-HSR 220031
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: AstraZeneca
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 5/19/22–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
11. A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
  - a. Project Number: MARIPOSA-2, UVA IRB-HSR 210388
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Janssen
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 1/27/22–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
12. HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC)
  - a. Project Number: HERTHENA-Lung01, UVA IRB-HSR 210052
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Daiichi Sankyo
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 5/20/21–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
13. Real-World Study of Early-Stage (I, II, III) Non-Small Cell Lung Cancer (NSCLC): Prevalence of EGFR Mutations, Treatment and Outcomes
  - a. Project Number: RTI International, UVA IRB-HSR 23020
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: AstraZeneca
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 5/6/21–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
14. CHIO3 Trial: CHEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
  - a. Project Number: AFT-64, UVA IRB-HSR 200304
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Alliance Foundation
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 3/25/21–
  - f. Total Award Amount:
  - g. Person Months: 0.12

15. A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
  - a. Project Number: TAK0788-301, UVA IRB-HSR 190098
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Takeda
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 2/4/20–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
16. Real-time Monitoring and Modeling of Symptoms and Adverse Events in Lung Cancer Patients Receiving Oral Targeted Therapies for Tumors with EGFR mutations or ALK Rearrangements
  - a. Project Number: UVA Lung001, UVA IRB-HSR 210257
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Lung Cancer Research Foundation/Pfizer
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 1/1/20–
  - f. Total Award Amount:
  - g. Person Months: 1.2
  
17. A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
  - a. Project Number: AP32788-15-01, UVA IRB-HSR 21211
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Takeda
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 1/16/19–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
18. A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
  - a. Project Number: MK3475-587, UVA IRB-HSR 20823
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Merck
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 10/13/18–
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
19. A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495, KeyImPaCT)
  - a. Project Number: MK3475-495, UVA IRB-HSR 20831
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Merck

- d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 9/14/18–
  - f. Total Award Amount:
  - g. Person Months: 0.12
20. EA5161: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
- a. Project Number: NCI-2017-02367/EA-5161, UVA IRB-HSR 20779
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: ECOG/ACRIN (NCI)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 6/11/18–
  - f. Total Award Amount:
  - g. Person Months: 0.12
21. A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
- a. Project Number: MK3475-671, UVA IRB-HSR 20474
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Merck
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 4/19/18–
  - f. Total Award Amount:
  - g. Person Months: 0.12
22. Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB- IIIA Non-small Cell Lung Cancer (ANVIL)
- a. Project Number: NCI-2015-01916/EA5142, UVA IRB-HSR 10955
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: ECOG-ACRIN (NCI)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 6/15/16–
  - f. Total Award Amount:
  - g. Person Months: 0.12

### **C. Completed Projects**

1. An Open-label, Multi-center, Rollover Study in Subjects with Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study
- a. Project Number: JTX-2011-R01, UVA IRB-HSR 220015
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Jounce Therapeutics
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 3/23/22–11/18/22
  - f. Total Award Amount:
  - g. Person Months: 0.12



2. Characterizing Association Between Early Endpoints and Overall Survival And Event-Free Survival In Resectable Non-Small Cell Lung Cancer (NSCLC)
  - a. Project Number: CA209-7L9, UVA IRB-HSR 23021
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Bristol Myers Squibb
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 2/24/21–3/8/23
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
3. Phase I trial of entinostat with carboplatin, etoposide, atezolizumab for extensive-stage small cell lung cancer
  - a. Project Number: ETCTN 10399, UVA IRB-HSR 210064
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: NCI
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 3/15/21–3/7/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
4. Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer
  - a. Project Number: JTX-2011-201(EMERGE), UVA IRB-HSR 21811
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Jounce Therapeutics
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 10/16/19–4/25/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
5. A phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium
  - a. Project Number: BTCRC-LUN17-139, UVA IRB-HSR 21757
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Big Ten Research Consortium (BTCRC)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 9/10/19–9/9/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
  
6. A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer
  - a. Project Number: HCRN-LUN17-302, UVA IRB-HSR 21719
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Hoosier Cancer Research Network (HCRN)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 8/19/19–8/18/22
  - f. Total Award Amount:

- g. Person Months: 0.12
- 7. LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  - a. Project Number: NCI-2018-01540, UVA IRB-HSR 21338
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: SWOG (NCI)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 2/14/19–6/15/20
  - f. Total Award Amount:
  - g. Person Months: 0.12
- 8. A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
  - a. Project Number: ANAM-17-20, UVA IRB-HSR 21243
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Helsinn
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 1/17/19–5/4/21
  - f. Total Award Amount:
  - g. Person Months: 0.12
- 9. A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
  - a. Project Number: NCI-2016-01325/ETCTN 10021, UVA IRB-HSR 20067
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: NCI
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 9/15/17–3/2/23
  - f. Total Award Amount:
  - g. Person Months: 0.12
- 10. Retrospective Review of Rate of Central Nervous System (CNS) Edema for Patients with Non-Small Cell Lung Cancer (NSCLC) and Melanoma who are Receiving Check Point Inhibitors (CPI) at the University of Virginia
  - a. Status: Project completed. Abstract poster discussion presented at ASCO 2018. Second abstract poster with updated results: IASLC 2021 World Conference on Lung Cancer.
  - b. Project Number: UVA IRB-HSR 19816
  - c. Name of PD/PI: Gentzler, Ryan
  - d. Roles: PI, faculty mentor for IM resident Sumner Abraham, recipient of DOM Resident Research Award,
  - e. Project Start and End Date: 4/20/17–3/28/23
- 11. A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor

- a. Project Number: NCI-2015-01270/ETCTN 9903, UVA IRB-HSR 19574
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: NCI
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 02/01/17– 9/29/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
12. Evaluating changes in the tumor immune microenvironment after neoadjuvant chemotherapy exposure in patients with resected lung cancer.
- a. Status: Project Completed. Abstract poster presented at ASCO-SITC conference, January 2018.
  - b. Project Number: IRB HSR18346
  - c. Role: PI, faculty mentor for hematology/oncology fellow, Michael Devitt
  - d. Funding: UVA Cancer Center Trainee support grant and IM resident Kristine Gade, recipient of DOM Resident Research Award.
  - e. Dates 8/12/16– 9/29/18
13. Phase I/II study of carboplatin/nab-paclitaxel and pembrolizumab for patients with advanced non-small cell lung cancer (NSCLC)
- a. Project Number: HCRN LUN13-175, UVA IRB-HSR 18368
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Hoosier Cancer Research Network (HCRN)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 3/16/16–12/5/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
14. Consolidation Pembrolizumab Following Chemoradiation in Patients with Inoperable/ Unresectable Stage III NSCLC
- a. Project Number: HCRN LUN14-179, UVA IRB-HSR 19011
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Hoosier Cancer Research Network (HCRN)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 01/01/16– 06/5/21
  - f. Total Award Amount:
  - g. Person Months: 0.12
15. Quality improvement: Evaluating time from presentation to initial treatment for patients with Stage I-IV non-small cell lung cancer at UVA medical center
- a. Status: Project completed. Abstract poster presented at ASCO Quality Symposium 2017.
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Role: PI; Faculty mentor for Geda Tola, undergraduate student and intern
  - d. Dates: 10/12/15–3/21/17
16. A Phase I/II Study of Pembrolizumab (MK-3475) in Combination with Chemotherapy or Immunotherapy in Participants with Lung Cancer (MK-3475-021/KEYNOTE-021)
- a. Project Number: MK3475-021, UVA IRB-HSR 17991
  - b. Name of PD/PI: Gentzler, Ryan

- c. Source of Support: Merck
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 05/18/15–2/28/23
  - f. Total Award Amount:
  - g. Person Months: 0.12
17. Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
- a. Project Number: NCI-2014-00627, UVA IRB-HSR 17857
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: SWOG (NCI)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 01/14/15–8/25/20
  - f. Total Award Amount:
  - g. Person Months: 0.12
18. A Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)
- a. Project Number: CA209-153, UVA IRB-HSR 17638
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: Bristol Myers Squibb
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 10/13/14–9/30/22
  - f. Total Award Amount:
  - g. Person Months: 0.12
19. Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer.
- a. Project Number: NCI-2012-01985/E2511, UVA IRB-HSR 17105
  - b. Name of PD/PI: Gentzler, Ryan
  - c. Source of Support: ECOG-ACRIN (NCI)
  - d. Primary Place of Performance: University of Virginia
  - e. Project Start and End Date: 01/01/14–4/7/17
  - f. Total Award Amount:
  - g. Person Months: 0.12

#### **D. Approved Projects in Development**

- 1. Phase II study of novel agent as salvage therapy for patients with metastatic squamous NSCLC
  - a. Status: Pending contract negotiation with sponsor
  - b. Project Number: PrE0509
  - c. Role: National PI
  - d. Co-PI: Khan, Saad (Stanford University)
  - e. Project Start and End Date: TBD

#### **E. Research Collaboration/Team Science**

- 1. **National Oncology Cooperative Research Groups**
  - a. ETCTN (NCI Experimental Therapeutics Clinical Trials Network)

- i. Member, UVA sub-site, 2015-2019
    - ii. mPI on UM1 grant 2020–2026
      - a. Contact PI: Michael Carducci, Johns Hopkins University
    - iii. Site PI, UVA, 2020–Present
    - iv. UVA Disease Focused Clinical Investigator (DFCI), Lung Cancer, 2020–Present
    - v. JHU-LAO, Lung Disease-Focused Investigator Group Lead, 2020–Present
    - vi. Study Chair/PI, ETCTN 10399, 2020–2022
      - a. Phase I trial of entinostat for SCLC
  - b. ECOG-ACRIN (NCI NCTN)
    - i. Member, Thoracic Committee 2013–Present
    - ii. Study Chair/PI, PrECOG 0509, 2020–Present
      - a. Co-PI, Saad Kahn, MD, Stanford University
      - b. Phase II trial of novel agent for squamous NSCLC
      - c. Status: in development
  - c. Hoosier Cancer Research Network (HCRN)
    - i. Co-Chair, Thoracic Trials Working Group, June 2020–Present
    - ii. Member, Thoracic Committee, 2013–Present
    - iii. Study Co-chair, HCRN LUN 13-175, 2013–2023
      - a. Co-chair: Nisha Mohindra, Northwestern University
      - b. Phase I/II trial of carboplatin, nab-paclitaxel, and pembrolizumab for patients with NSCLC
      - c. Status: Study completed, 2 abstracts presented, manuscript published
    - iv. Study Chair, HRCN LUN23-618, 2023–
      - a. Phase II trial of novel agent for NSCLC brain metastases
      - b. Status, Open to accrual at UVA May 2024; pending activation at other sites
- 2. **Lung Cancer Clinical Research Team, UVA Cancer Center**
  - a. Director, Thoracic Medical Oncology Clinical Research
    - i. August 2017–Present
    - ii. In this role, I oversee the clinical research activities including clinical trials, translational, and retrospective projects for our group. Members include co-investigator Richard Hall, fellows, residents, medical students, clinical research coordinators, nurses, nurse practitioner, clinical pharmacist
  - b. Co-Leader, lung cancer clinical research team
    - i. February 2015–August 2017
- 3. **Lung Cancer Translational Research Team, UVA Cancer Center**
  - a. Chair, Founding member, April 2019–Present
    - i. Monthly meetings discussing active research projects and proposals across cancer center members focused on basic science and translational research focused on lung cancer
    - ii. Allocation of cancer center funding for high priority research involving lung cancer. Annual RFP, grant application review, and awarding of funding

4. **Cancer Center Team Science Award (CaTS)**
  - a. Title: Combinatorial Therapy for Lung Cancer
  - b. PI: Timothy Bullock, PhD
  - c. Role: Co-Investigator
  - d. Description: Team science award to build a program that leverages UVA's expertise in cancer immunology to the unmet need of NSCLC
  
5. **Co-investigator, UVA clinical trials:**
  1. KEYVIBE 008: Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    - a. NCT 05224141, UVA IRB 220218
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 10/18/2022 – present
  2. Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic NSCLC Without Actionable Genomic Alterations: TROPION Lung 01
    - a. NCT 04656652, UVA IRB 210042
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 6/10/2021 – present
  3. A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
    - a. NCT 04317534, UVA IRB 200297
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 11/25/2020 – present
  4. Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
    - a. NCT 04267848, UVA IRB 200238
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 9/1/2020 - present
  5. Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
    - a. NCT 04092283, UVA IRB 20159
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 5/26/2020 – present
  6. ETCTN 10216: A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant NSCLC
    - a. NCT 03831932, UVA IRB 200081
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 4/15/2020 – present

7. An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
  - a. NCT 03909334, UVA IRB 200034
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 5/12/2020 – present
8. Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous NSCLC with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
  - a. NCT 03906071, UVA IRB 21856
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 02/07/2020 – present
9. ETCTN 10166: A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory NSCLC
  - a. NCT 03600701, UVA IRB 20921
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 9/1/2018 – present
10. ECOG-ACRIN 5162, Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with *EGFR* Exon 20 Insertion Mutations
  - a. NCT 03191149, UVA IRB 20667
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 5/8/2018 – present
11. ALCHEMIST Trial (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial)
  - a. NCT 02194738 (UVA IRB 17719), NCT 02193282 (UVA IRB 17720), NCT 02201992 (UVA 17721)
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 10/31/2014 – present
12. Healthcare Resource Utilization and costs among patients treated with EGFR-TKIs in EGFRm metastatic NSCLC: A Multi-Site Observational Study Across Comprehensive Cancer Centers
  - a. UVA IRB 22004
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 11/22/2019 – 6/30/2022
13. NRG LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation vs Chemoradiation Plus Atezolizumab
  - a. NCT 03811002, UVA IRB 21753
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 7/19/2019 – 6/23/2023
14. SWOG 1619: A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma.

- a. NCT 03228537, UVA IRB 21441
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 5/13/2019 – 8/19/2020
15. AFT-16: Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent
    - a. NCT 03102242, UVA IRB 20307
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 3/28/2018 – 6/18/2019
  16. ETCTN 9974: A phase II study of Olaparib Plus Cediranib in Combination with Standard Chemotherapy for SCLC
    - a. NCT 02899728, UVA IRB 19883
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 1/12/2018 – 5/4/2020
  17. ECOG-ACRIN 5163 (INSIGNA): Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous NSCLC
    - a. NCT 03793179, UVA IRB 21434
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 3/11/2019 – 12/31/2022
  18. KEYNOTE 789: A Randomized, Double-Bind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI Resistant EGFR-mutated Tumors in Metastatic Non-squamous NSCLC
    - a. NCT 03515837, UVA IRB 20719
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 6/20/2018 – 7/24/2019
  19. A Pilot Study to Detect Circulating Tumor Cells (CTCs) and Cancer Derived Material (CDM) in Patients with Stage IV NSCLC
    - a. UVA IRB 18445, part of the ORIEN Project
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 11/27/2017 – 12/31/2019
  20. KEYNOTE 189: A Randomized, Double-Blind, Phase III Study of Platinum + Pemetrexed Chemotherapy with or without Pembrolizumab (MK34-75) in First Line Metastatic Non-squamous NSCLC
    - a. NCT 02578680, UVA IRB 18772
    - b. PI: Hall, Richard
    - c. Role: Co-I
    - d. Dates: 6/29/2016 – 2/6/2017
  21. SCRX001-002 Study: An Open Label, Single-arm, Phase II Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpitizumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing SCLC
    - a. NCT 02674568, UVA IRB 18744



- b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 5/4/2016 – 5/31/2017
22. X396: Phase I/II Study of X-396, A Selective, Second Generation ALK Inhibitor in NSCLC
- a. NCT 01625234, UVA IRB 18502
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 2/24/2016 – 12/15/2017
23. TIGER 3: A Phase III, Open Label, Multicenter, Randomized Study of Oral Rocelitinib (CO-1686) Monotherapy vs Single Agent Cytotoxic Chemotherapy in Patients with Mutant EGFR NSCLC and Failure of at Least 1 Prior EGFR TKI and Platinum Doublet Chemotherapy.
- a. NCT 02322281, UVA IRB 18371
  - b. PI: Hall, Richard
  - c. Role: Co-I
  - d. Dates: 10/2/2015 to 5/5/2016
24. LUN 288: A Phase II Study of the Combination of LY3023414 and Nectinmumab after First Line Chemotherapy for Metastatic SCC NSCLC
- 1. NCT 02443337, UVA IRB 18173
  - 2. PI: Hall, Richard
  - 3. Role: Co-I
  - 4. Dates: 7/22/2015 – 12/14/2016
25. Isolation and Characterization of Extracellular Vesicles Associated with Brain Metastases
- a. UVA HSR21676
  - b. PI: Fadul, Camilo
  - c. Role: Co-I
  - d. Dates:
26. A Phase Ib Dose-Escalation Study of Cabozantinib (EX184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
- a. Project Number: XL184
  - b. Sponsor: Exelixis
  - c. PI: Dreicer, Robert
  - d. Role: Co-I
  - e. Dates: 2018–
27. A Phase 1/2A, Multicenter, open-label study of LYC-55716 in adult subjects with locally advanced or metastatic cancer
- a. Project Number: LYC-55716-1001
  - b. Sponsor: Lycera
  - c. PI: Duska, Linda
  - d. Role: Co-I
  - e. Dates: 3/24/18–
28. A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies
- a. Project Number: UVA IRB-HSR 18488
  - b. Sponsor: UVA
  - c. PI: Lerner, James
  - d. Role: Co-I

- e. Dates: 9/12/17–
- 29. A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell
  - a. Project Number: M14-360
  - b. Sponsor: AbbVie
  - c. PI: Larner, James
  - d. Role: Co-I
  - e. Dates:
- 30. A Decision Aid with Health Related Quality of Life (HRQL) Assessment to Reduce Costs in the Treatment of NSCLC
  - a. Project Number: R01CA157409-01A1
  - b. Sponsor: NIH
  - c. PI: Hollen, Patricia
  - d. Role: Co-I
  - e. Dates: 9/14/12–4/16/18

**6. Other Collaborative Projects, Co-investigator**

UVA IRB-HSR 13310                      Moskaluk (PI)  
NCI-NIH  
NHLBI-NIH  
Identification of Biomarkers in Diseased Human Specimens  
Role: Co-I

UVA IRB-HSR 21406                      Barnes (PI)  
NIH  
Multiscale Modeling and Intervention for Improving Long-Term Medication Adherence and Adverse Event Monitoring  
Role: Co-I

UVA IRB-HSR 19083                      Hall (PI)  
Retrospective Review of Clinical Outcomes for Patients with Non-Small Cell Lung Cancer (NSCLC) at the University of Virginia  
Role: Co-I

UVA IRB-HSR 18465                      Hall (PI)  
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) at the University of Virginia: An Extension Database of the Cancer Registry  
Role: Co-I

UVA IRB-HSR 18346                      Slingsluff (PI)  
Immune infiltration and expression of immune relevant proteins in lung non-small cell lung cancer  
Role: Co-I

UVA IRB-HSR 18272                      Slingsluff (PI)  
Promising biomarkers for immune signatures and response to pembrolizumab.

Role: Co-I

## IX. TEACHING ACTIVITIES

### A. Classroom, Seminar, or Teaching Laboratory

MS 2 lecture "Lung Tumors, Mediastinal Masses: Benign and Malignant Diagnosis and Therapy"	2 hours	33% responsibility	2016
MS 2 lecture "Lung Cancer, Part 1"	1 hour	100% responsibility	2017
MS 2 lecture "Lung Cancer, Advanced Stage and Immunotherapy"	1 hour	100% responsibility	2018
MS 2 lecture "Systemic therapy, adjuvant and advanced stage lung cancer"	1 hour	100% responsibility	2019
MS 2 Interactive case-based lecture "61-yr Old with new lung cancer diagnosis"	2 hours	25% responsibility	2019
MS 2 lecture "Systemic therapy, adjuvant and advanced stage lung cancer"	1 hour	100% responsibility	2020

### B. Clinical Teaching (in ward, clinic, OR)

1. Continuity Clinic fellows, ½ day per week for 6 months  
Fellows typically see between 6-8 clinic patients per session, including 1-2 initial visits and 4-6 follow-up. Fellows learn to review charts, outside records, perform a history and physical examination, determine cancer stage, personally review radiology imaging and measure for response assessments, make treatment recommendations, and manage toxicity associated with cancer therapies. Fellows also learn to work as part of a team of nurse coordinators, nurse practitioners, and other care team providers.
  - a. Michael Devitt, Fall 2015
  - b. Andrew Romano, Fall 2015
  - c. Louise Man, Spring 2016
  - d. Lindsay Hathaway, Fall 2016
  - e. Athar Naeem, Fall 2016 and Spring 2017
  - f. Laura Talamo, Spring 2017
  - g. Trish Millard, Spring 2017
  - h. Erin McLoughlin, Fall 2017
  - i. Carolyn Carrera, Fall 2017
  - j. Abeer Alfaraj, Spring 2018
  - k. Erin McLoughlin, Spring 2018
  - l. Joey Mock, Fall 2018
  - m. Erin McLoughlin, Fall 2019
  - n. Pooja Mehra, Fall 2020
  - o. Nicholas Schmidt, Spring 2021
  - p. Lindsey Shantzer, Fall 2021
  - q. David Riley, Spring 2022
  - r. Phillip Young, Fall 2022

- s. Sean Dougherty, Fall 2023
2. Thoracic Oncology Block Clinic  
Fellows rotate for 1-2 months at a time and spend 2-3 half-days per week with me in clinic. Roles/responsibilities are the same as the Continuity Clinic fellows, as described above.
- a. Erin McLoughlin, February - March 2019
  - b. Carolyn Carrera, April 2019
  - c. Abeer Alfaraj, April 2019
  - d. Puja Arora, May 2019
  - e. Erin McLoughlin, June-July, 2020
  - f. Lindsey Shantzer, August-September, 2020
  - g. Eric Pierce, October-November, 2020
  - h. Pooja Mehra, April-May, 2021
  - i. Joey Mock, April-May, 2021
  - j. Chris Thomas, November-December, 2021
  - k. Eric Pierce, March-April, 2022
  - l. Christian Barlow, April-May, 2022
  - m. Will Thomas, August-September, 2022
  - n. Samantha DiBenedetto, December 2022 to June 2023
  - o. Jenna Schlefman, March 2023 to May 2023
  - p. Jeffrey Lantz, May 2023 to June 2023
  - q. Gautham Prakash, August 2023
  - r. Jack Masur, October 2023 to November 2023
  - s. Valerie Tran, January to February 2024
  - t. Nate Roberts, January to February 2024
  - u. Will Thomas, April 2024
3. Inpatient Oncology Service  
I attend on inpatient oncology service and oversee 8 internal medicine residents (4 residents, 4 interns) and medical students on their internal medicine rotation.
- a. 6-7 weeks per year, 2014–2018
  - b. 4 weeks per year, 2018–2022
  - c. 3 weeks per year, 2023–Present
4. Inpatient Oncology Consult Service  
Disease-specific staffing on inpatient oncology consults on our fellow-run consult service. Split coverage with Dr. Hall. I see consults the 2nd half of every calendar month, averaging 4-5 consults per month
- a. UVA Hospital, 2015–Present

## **X. TEACHING ACTIVITIES OTHER THAN CLASSROOM OR CLINICAL, INCLUDING TEACHING OF UNDERGRADUATE (PRE-BACCALAUREATE), GRADUATE, POSTDOCTORAL STUDENTS AND CONTINUING EDUCATION MEDICAL STUDENTS**

### **A. Conferences, Grand Rounds, Journal Clubs, etc.**

UVA Department of Medicine, Resident Lecture Series

2014–Present

One hour didactic lecture for residents and medical students rotating on the inpatient hematology/oncology service. Topics include: lung

cancer, clinical trials, cancer therapeutics.

1. Lectures given every other month, 2014–2020
2. Lectures given 2-3 times per year, 2020–Present

Hem/Onc Fellows Lecture Series

Three one-hour lectures during month-long lung cancer education block to hematology/oncology fellows each year 2014–Present

1. Operative and Stage III NSCLC
2. Stage IV, 1<sup>st</sup> line
3. Stage IV, 2<sup>nd</sup> line and beyond

Hem/Onc Fellows Journal Club

2 lung cancer journal articles, one hour, annually

2015–Present

Hem/Onc Fellows Lecture

“Phase II Studies: Objectives, Designs, Endpoints”

2023

Hem/Onc Fellows Lecture

“Statistics for the Clinical Investigator”

2023

Thoracic Surgery Resident Lecture

“Stage IV Lung Cancer”

2022

Hem/Onc Fellows Lecture

“Phase II Studies: Objectives, Designs, Endpoints”

2022

Hem/Onc Fellows Lecture

“Statistics for the Clinical Investigator”

2022

Thoracic Surgery Resident Lecture

“Stage IV Lung Cancer”

2021

Heme/Onc Fellows Lecture

“Phase II trial designs, endpoints, and pitfalls”

2021

Hem/Onc Fellows Lecture

“Statistics for the Clinical Investigator”

2021

Thoracic Surgery Resident Lecture

“Stage IV Lung Cancer”

2020

UVA Cancer Center Molecular Tumor Board

“Dual Oncogenic Drivers in Lung Cancer”

2019

UVA Cancer Center Molecular Tumor Board

“A Case of MET-mutated NSCLC and review of MET as a therapeutic target”

2019

Hem/Onc Fellows Lecture

“Statistical Considerations for Oncology Clinical Trials”

2019

<u>UVA Cancer Center Molecular Tumor Board</u> “Molecular Targets in Lung Cancer”	2019
<u>Engineering in Medicine, Lung Cancer Workshop</u> “Overview of clinical research topics in NSCLC”	2019
<u>UVA Cancer Center Molecular Tumor Board</u> “Targeting RET-rearranged non-small cell lung cancer”	2018
<u>Pathology Resident Lecture</u> “Immunotherapy for lung cancer and the role of PDL1 testing”	2017
<u>Radiology Nursing Conference, UVA</u> “Lung cancer biopsies and the ongoing need for more tissue”	2016
<u>Radiation Oncology Resident Lecture</u> “Immunotherapy for Lung Cancer”	2016
<u>Cancer Center Genetics and Cell Signaling Lecture Series</u> “Targeted Therapy for Advanced NSCLC”	2015
<u>Thoracic Tumor Board, UVA Cancer Center</u> “Adjuvant Chemotherapy for Stage I NSCLC”	2015
<u>Thoracic Tumor Board, UVA Cancer Center</u> “The need for up-to-date and expeditious reflex molecular testing for NSCLC”	2014

**B. Teaching Committees**

Hematology/Oncology Fellowship Program Evaluation Committee (PEC)	2014–2019
Hematology/Oncology Fellowship Program Clinical Competency Committee (CCC)	2016–2017

**C. Other, including development of curriculum or new teaching materials, methods of evaluation, program supervision, etc.**

1. Hematology/Oncology Fellows, Disease Specific Lecture Series
  - a. Lung cancer curriculum and lectures
  - b. In 2014, in collaboration with Richard Hall, developed curriculum and lecture series covering relevant topics in lung cancer for hematology/oncology fellows, compiled relevant journal articles
    - i. Curriculum, objectives, reference articles updated annually, 2014–Present
2. Hematology/Oncology Fellows, Statistics Lecture Series
  - a. In 2019, created new lecture, “Statistical Considerations for Oncology Clinical Trials”
    - i. Created two handouts
      - a. “A Guide to Article Reviews”
      - b. “Trial Statistical Considerations”
  - b. 2020-2023 lecture series revised
    - i. Two lectures:

- a. “Statistics for the clinical investigator”
  - b. “Phase II designs, endpoints, and pitfalls”
3. CME Course: ASCO Education, Expert Answers
  - a. Topic: Localized Lung, adjuvant immunotherapy
    - i. Course planner (faculty) for CME course included in ASCO Education Online Platform covering new data for adjuvant immunotherapy from the IMpower010 trial, 0.5 CME credit course
    - ii. Published September 7, 2021
    - iii. <https://education.asco.org/product-details/adjuvant-therapy-for-early-stage-lung-cancer>
4. Cancer.net, patient education
  - a. ASCO’s patient education website, Cancer.net
  - b. Editorial Board Member
    - i. Specialty Editor, “Thymoma”, 2021–Present
      - a. <https://www.cancer.net/cancer-types/thymoma/view-all>
    - ii. Advisory Panelist, “Lung Cancer”, 2020–Present
      - a. <https://www.cancer.net/cancer-types/lung-cancer/view-all>
    - iii. Editor, “Fluid Around the Lungs or Malignant Pleural Effusion”, September 2021
      - a. <https://www.cancer.net/coping-with-cancer/physical-emotional-and-social-effects-cancer/managing-physical-side-effects/fluid-around-lungs-or-malignant-pleural-effusion>
    - iv. Podcast, “Molecular Testing,” 4/1/22
      - a. Role: Discussion leader with co-panelists
      - b. <https://www.cancer.net/blog/2022-06/clinical-trials-molecular-testing-early-stage-lung-cancer-impower010-adaura-and-checkmate-816>
5. TheMedNet contributor
  - a. Online oncology physician-led education, tumor boards
  - b. Invited commentary, IMpower010 trial, December 2021
  - c. 4,620 content views, 1,045 physicians reached as of 7/1/23
  - d. <https://www.themednet.org/user/user/view/id/18831?tab=Recent-Activity>
6. X (formerly Twitter) contributor, @ryangentzler
  - a. Social media, educational commentary regarding lung cancer for physicians and patients in the lung cancer and oncology communities
  - b. 708 followers as of 7/1/23
  - c. <https://twitter.com/ryangentzler>

## **XI. OTHER PROFESSIONAL ACTIVITIES (BOARDS, EDITORSHIPS, ETC.)**

### **A. Ad hoc Reviewer**

1. *Clinical Lung Cancer*, 19 manuscripts
  - a. February 2024, October 2023, September 2023, May 2023, February 2023, August 2022, July 2022, February 2022, January 2022, October

- 2021, July 2021, May 2021, January 2021, June 2020, April 2020, March 2020, November 2019, November 2019, February 2018
2. *The Oncologist*, 3 manuscripts
    - a. January 2024, October 2023, November 2020
  3. *Cancer*, 16 manuscripts
    - a. August 2023, July 2023, May 2023, May 2023, November 2022, August 2022, July 2022, November 2021, September 2021, August 2021, July 2021, February 2021, January 2019, July 2018, November 2017, May 2015
  4. *JAMA Open*
    - a. January 2023
  5. *Drugs of Today*
    - a. July 2022
  6. *JAMA Oncology*
    - a. March 2022
  7. *The American Journal of Medical Sciences*
    - a. January 2022
  8. *Precision Cancer Medicine*
    - a. December 2021
  9. *Journal for ImmunoTherapy of Cancer (JITC)*, 4 manuscripts
    - a. April 2021, June 2020, November 2019, April 2019
  10. *Journal of Clinical Oncology*
    - a. December 2020
  11. *Clinical Cancer Research*
    - a. November 2020
  12. *Translational Cancer Research*
    - a. September 2020
  13. *Cancer Management and Research*
    - a. June 2020
  14. *JCO Precision Oncology*
    - a. May 2020
  15. *Journal of Clinical Medicine*
    - a. May 2020
  16. *Lung Cancer*, 2 manuscripts
    - a. December 2019, April 2019
  17. *Frontiers in Oncology*, 2 manuscripts
    - a. July 2019, May 2018
  18. *Journal of Neuro-Oncology*
    - a. July 2019
  19. *Case Reports in Oncological Medicine*
    - a. May 2019
  20. *Cancer Medicine*
    - a. October 2017
  21. *Cellular Physiology and Biochemistry*
    - a. September 2017
  22. *Scientific Reports*
    - a. May 2017
  23. *Drugs*
    - a. June 2016
  24. *Translational Cancer Research*
    - a. May 2016



25. *Cancer Treatment and Research Communications*
  - a. April 2016
26. *Cancer Investigation*
  - a. October 2014
27. Book review: Emerging Cancer Therapeutics: Lung Cancer. *Doody's Review Service* (on-line). Available: <http://www.doody.com/DRS>. July 2012.

## **XII. CLINICAL ACTIVITIES**

### **A. Inpatient**

1. Oncology Inpatient Service
  - a. 6-7 weeks per year 2014–2017; 4 weeks/year, 2017–2023, 3 weeks/year, 2023–Present
  - b. UVA Hospital, Oncology unit and overflow to other floors
  - c. Supervise residents and manage patients admitted to inpatient solid tumor oncology service
  - d. Interface with referring physicians from UVA, outside oncologists, ER physicians, or other providers to accept and facilitate care for patients requiring transfer to UVA
2. Thoracic Oncology Consults
  - a. 26 weeks per year
  - b. UVA Hospital
  - c. Supervise hematology/oncology fellows, management of patients with lung cancer and other solid tumor malignancies requiring inpatient oncology consultation.
  - d. Interact with primary service attendings and make recommendations for management of patients with new oncologic diagnoses or established oncology patients.

### **B. Outpatient**

1. Emily Couric Clinical Cancer Center, 2 full days (4 half-days) per week
  - a. Tuesday AM/PM, Wednesday AM/PM
  - b. Manage patients with lung cancer or other thoracic malignancies.
  - c. Collaboration and oversight of team members, including nurse care coordinator, patient access coordinator, medical assistants, infusion nurse, nurse practitioner, clinical pharmacist

## **XIII. COMMITTEES & COUNCILS**

### **A. University**

Institutional Review Board for Health Sciences Research (IRB-HSR) 2015–2022  
University of Virginia  
Role: Full board member  
*Monthly 3-hour meetings*

Engineering in Medicine Seed Grant Program March 2018  
University of Virginia  
Role: Scientific Reviewer  
*Reviewed and scored grant applications with particular focus on cancer research*

**B. UVA Health**

Protocol Review Committee 2020–Present

UVA Cancer Center

Role: Chair

*Chair of institutional peer-review committee required by NCI as part of the Cancer Center’s protocol review and monitoring system (PRMS). Review and oversight of all cancer-related clinical research protocols, including scientific review, prioritization, and performance monitoring.*

Lung Cancer Translational Research Team 2019–Present

UVA Cancer Center

Role: Chair

*Monthly meetings to discuss active lung cancer research projects and proposals from Cancer Center members to foster collaboration and grant applications*

Genomics Steering Committee 2019–Present

UVA Health System

Role: Member

Chair: Eli Williams

*Quarterly meetings to discuss plans to implement genomic testing for patients with solid tumors. Committee members include molecular pathologists and medical oncologists*

ORIEN Advisory Committee 2019–Present

UVA Cancer Center

Role: Member

Chairs: Christopher Moskaluk, Elizabeth Mulcahy

*Quarterly meetings to advise the PI and administrators of the Oncology Research Information Exchange Network (ORIEN) project team at UVA*

Urgent Symptom Management Workgroup 2019

UVA Cancer Center

Role: Member

Chair: Christiana Brenin

*Monthly 1-hour meetings to plan the development of an urgent symptom management clinic for the UVA Cancer Center*

Beacon Operations Workgroup 2018–2020

UVA Cancer Center

Role: Member, Medical Oncologist

Director: Devon Bloxsom

*Monthly 1-hour meetings to review, approve, and implement proposed updates to EPIC electronic medical record as they relate to cancer center clinical care*

Clinical Leaders Council 2017–2018

UVA Cancer Center

Role: Co-Leader, Thoracic Oncology

Director: Reid Adams

*Monthly 2-hour meetings with senior cancer center leadership and disease team leaders to discuss current issues related to cancer center members*

Beacon Oversight Council

2015–2021

UVA Cancer Center

Role: Thoracic Disease Team representative

Director: Kathlene DeGregory

*Monthly 1-hour meetings to review issues related to oncology chemotherapy treatment plans and systematic review and updates to outdated plans for use across the UVA Health System*

Protocol Review Committee (PRC)

2015–2019

UVA Cancer Center

Director: David Schiff

Role: Full board member

*Monthly 1-hour meetings*

Pharmacy & Therapeutics (P&T) Committee

2014–2020

UVA Health System

Hematology/Oncology Sub-committee

Role: Co-chair, October 2018–October 2020,

Member, December 2014–October 2018

Chair: Varinder Kaur

*Quarterly 1-hour meetings; represent Hem/Onc Committee at general P&T meetings twice per year*

Clinical Trial Feasibility Committee

2014–2015

UVA Cancer Center, Office of Clinical Research

Role: Founding member

Director: Geoffrey Weiss

*Bi-weekly 1-hour meetings to discuss hem/onc division clinical trial portfolio and assess proposed new trials for feasibility*

Thoracic Multidisciplinary Tumor Board

2014–Present

UVA Cancer Center

Role: Medical Oncologist, member

Director: Linda Martin

*Weekly 1-hour meetings*

**C. Department**

Department of Medicine Compensation Committee

2024–Present

Role: Member

Director: Taison Bell, Mitch Rosner, Russ Manley

Representative for Division of Hematology/Oncology. Responsible for development, implementation, and review of Department- and Division-specific aspects of the compensation plan, such as incentive criteria.

Hem/Onc TeleMedicine Working Group

2020

Division of Hematology/Oncology

Role: Member

*Tasked with creating workflow and implementing in our hematology/oncology clinic in light of the challenges faced by COVID-19 and need to deliver care remotely via telemedicine.*

Thoracic Medical Oncology Clinical Research Program 2014–Present

Role: Director, August 2017–Present

Role: Member, August 2014–July 2017

*Weekly 1 hour meetings to discuss Thoracic Medical Oncology Research Program, clinical trials, review active patients on trials, adverse events, trial-related assessments, regulatory compliance, data collection/management*

Hematology/Oncology Fellowship Core Competency Committee (CCC) 2016–2017

Role: Member

*Met twice annually to review fellow performance according to ACGME milestones*

Quality Committee, Hematology/Oncology 2015–2020

Role: Member

*Monthly 1-hour meetings to review and implement Hem/Onc Division Quality improvement projects*

Hematology/Oncology Fellowship Program Evaluation Committee (PEC) 2014–2017

Role: Member

*Six 1-hour meetings per year, to discuss education curriculum and propose changes based on fellow and faculty evaluations*

#### **D. National**

IASLC 2024 World Conference on Lung Cancer (WCLC) 2023–Present

Program Committee

Role: Program Committee Track Co-Chair, Local-Regional Non-small Cell Lung Cancer track

*As a track Co-Chair, I facilitate and lead the planning of the Educational Sessions, join session planning call with session faculty (1 call per session), facilitate and lead the planning of the abstract sessions, facilitate compliance with ACCME standards by reviewing disclosures and documenting and mitigating any conflicts/potential conflicts for WCLC 2024.*

ASCO Advantage Education Program, Lung Cancer 2023

Role: Panelist, Small group discussion leader

*ASCO Advantage is a disease-state content, interactive, educational program offered by ASCO to corporate groups and other audiences. ASCO Advantage advances clinical cancer knowledge and builds confidence for clinical conversations with oncology treatment teams. Lead case-based small group sessions, panelist on several lectures*

IASLC 2023 North American Conference on Lung Cancer (NACLC) 2023

Program Committee

Role: Program Committee member

*Speaker and topic selections, abstract review, meeting track leader, promotion of meeting via email and social media.*

Lung Cancer Research Foundation,

2022

Minority Career Development Award Review

Role: ad hoc reviewer

*Reviewed and scored grant applications for minority CDA FY2022 grant cycle. This is a two-year career development award intended to support early-career scientists from underrepresented groups working in lung cancer and working in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research.*

ARTES Leadership Development Course, NCI/ETCTN

2022–Present

Role: Co-director

*ARTES is an annual leadership development course for early career investigators, developed under the auspice of the North America Star Consortium and the Johns Hopkins LAO of the NCI ETCTN network. Course covers time management, conflict resolution, and communication that are required to build a successful career. This course is being offered to early career investigators over a 6-month period.*

Journal of Clinical Oncology: JCO Meeting Abstracts

2021–Present

Role: Associate Editor

*To work with the Editor-in-Chief, Pamela Kunz, and ASCO staff to uphold editorial policies of the JCO Meeting Abstracts (formerly Meeting Proceedings), including conclusive title review and higher-level editorial decisions, including abstract errata and retractions, and raising awareness of abstracts through the ASCO website and social media. 5-year term.*

IASLC 2021 World Conference on Lung Cancer (WCLC)

2021

Program Committee

Role: Abstract Grader

*Reviewed and graded abstracts for conference in category: “Novel Therapeutics and Targeted Therapies”*

National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC)

2020–Present

Role: Member

*Assist with the design and prioritization of early phase drug development trials with agents for which the Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug application (IND)*

American Society of Clinical Oncology (ASCO)

2019–Present

Cancer.net Editorial Board

Role: 1) Advisory Panelist, Non-Small Cell Lung Cancer

2) Specialty Editor, Thymoma

*Two-year renewable term. Annually review and update disease-specific sections to ensure the medical content is accurate, timely, and complete.*

*Cancer.net is a free patient resource from ASCO that offers comprehensive, physician-approved educational information to patients and caregivers*

American Society of Clinical Oncology (ASCO) 2019–2022  
Annual Meeting Scientific Program Committee

Role: Member, “Lung Cancer - Non-small Cell Local-regional/Small Cell/Other” Track

*The committee reviews and selects abstracts for presentation at the Annual Meeting, reviews and grades submitted abstracts, and develops scientific sessions based on graded abstracts. The committee also plans, develops, and initiates the scientific sessions at the Annual Meeting.*

Department of Defense, Lung Cancer Research Program (LCRP) 2019

Role: ad hoc member, Programmatic Panel

*Invited to participate in the pre-application screening of FY19 LCRP grant applications*

NCI Experimental Therapeutics Clinical Trials Network (ETCTN) 2016–Present

Role: PI (Johns Hopkins LAO), Site PI (UVA), 3/2020 -2026

Member, co-investigator, 2016–Present

*PI on multi-PI NIH UM1 grant. Work with 4 other PIs to oversee the cooperative group and implementation of the grant. Also serve as the site PI for UVA and co-investigator on group clinical trials*

Eastern Cooperative Oncology Group (ECOG) 2014–Present

Thoracic Core Committee

Roles: Member, Co-investigator

*Co-investigator on group clinical trials, review ongoing trials and new proposals at semi-annual meetings, monthly conference calls*

Hoosier Cancer Research Network (HCRN) 2014–Present

Thoracic Working Group

Role: Co-Chair, June 2020–Present

Member, 2014–Present

*Co-investigator on group clinical trials, review ongoing trials and new proposals, monthly conference calls*

#### **XIV. FINANCIAL RESOURCES (GRANTS AND CONTRACTS)**

##### **A. Federal**

##### **1. Current**

mPI	The Experimental Therapeutics Clinical Trials Network (ETCTN), Johns Hopkins LAO NIH, 4UM1 CA186691-07 3/1/23–2/29/24 \$1,836,359
PI	Protocol Review & Monitoring System, University of Virginia Cancer Center NIH, 5P30CA044579-32, subproject 7842

2/1/23–1/31/24 \$65,865

2. Completed

- |      |  |
|------|--|
| mPI  | The Experimental Therapeutics Clinical Trials Network (ETCTN),<br>Johns Hopkins LAO<br>NIH, 3UM1 CA186691-06S2<br>3/1/20–2/28/23 \$125,000 |
| mPI  | The Johns Hopkins Translational Science Team for the ET-CTN<br>NIH, 3UM1 CA186691-06S1<br>3/1/20–2/28/23 \$99,789                          |
| mPI  | The Johns Hopkins Translational Science Team for the ET-CTN<br>NIH, 3UM1 CA186691-06<br>3/1/20–2/28/23 \$5,745,990                         |
| CoPI | Cancer Clinical Investigator Team Leadership Award (CCITLA)<br>NIH 3P30 CA004579-28S1<br>7/1/18–6/30/20 \$120,000                          |

**B. Other, External**

1. Current

- |    |   |
|----|---|
| PI | Real-time Monitoring and Modeling of Symptoms and Adverse<br>Events in Lung Cancer Patients Receiving Oral Targeted<br>Therapies for Tumors with EGFR mutations or ALK<br>Rearrangements<br>Lung Cancer Research Foundation<br>1/1/20–6/30/24 \$341,735 |
| PI | Investigator-initiated trial<br>HCRN LUN23-618: Phase II study of adagrasib plus SRS for<br>KRAS-mutated NSCLC with active brain metastases<br>Hoosier Cancer Research Network (HCRN), Mirati/BMS<br>5/1/24–4/30/30 \$                                  |

See Also, Section VIII: Research Activities, Current Projects above for grant funding from clinical trials and other projects.

**C. Other, UVA Internal**

1. Current

- |    |   |
|----|---|
| PI | Real-time Monitoring and Modeling of Symptoms and Adverse<br>Events in Lung Cancer Patients Receiving Oral Targeted<br>Therapies for Tumors with EGFR mutations or ALK<br>Rearrangements<br>1/1/20–6/30/24 \$20,000 |
|----|---|

**XV. PERSONNEL SUPERVISED**

**A. Hematology/Oncology Fellows**

1. Research Mentor

- a. Sean Dougherty, 2023-
  - b. Shipra Maheshwari, 2023-
  - c. Phillip Young, 2022-
  - d. Samantha Dibenedetto, 2021-
  - e. Eric Pierce, 2020
  - f. David Riley, 2019-2022
  - g. Joey Mock, 2018-2021
  - h. Daniel Reid, 2017
  - i. Erin McLoughlin, 2017-2020
  - j. Michael Devitt, 2015-2018
  - k. Louise Man, 2014-2017
2. Continuity Clinic Fellows, ½ day per week for 6 months
    - a. See list of residents above in clinical teaching section

#### **B. Internal Medicine Residents**

1. Research Mentor
  - a. Sumner Abraham, 2017-2020
  - b. Sabah Alakabi, 2018-2019
  - c. Kristine Gade, 2016-2018
  - d. Josh Reuss, 2015-2017

#### **C. Medical Students**

1. Research Mentor
  - a. Margaret Moore, 2017-2018
  - b. Jacob Zaemes, 2017-2018
  - c. Jacobi Hines, 2017-2018
2. Shadowing experience in Clinic
  - a. Chad Lehman, December 2022, 1 session

#### **D. Undergraduate Students**

1. Research Mentor
  - a. Geda Tola, 2015-2017
2. Shadowing Experience in Clinic
  - a. Chris Margraf, Summer 2018, 2 sessions
  - b. Geda Tola, Spring 2016, 4 sessions
  - c. Matt Dalton, Summer 2015, 4 sessions

#### **E. Advanced Practice Providers**

- a. Marie Thomas, NP,
  - i. ½ day per week, March 2018 through July 2018
    - a. Orientation/training in Oncology
  - ii. Full time nurse practitioner, August 2019–Present
- b. Margaret McLean, NP, Full-time nurse practitioner in thoracic medical oncology clinic, September 2016–May 2019

## **XVI. PAPERS PUBLISHED OR IN PRESS**

### **A. Peer Reviewed**

1. Maheshwari S, **Gentzler RD**. Optimal Front-Line Therapy for Non-Oncogene Driven NSCLC. *Advances in Oncology*, 2024;4(1):47-61.



2. Young P, Elghawy O, Mock J, Wynter E, **Gentzler RD**, Martin LW, Novicoff W, Hall R. Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. *Current Oncology*, 2024;31(1):260-273.
3. Passaro A, Jie Wang, Wang Y, Lee S-H, Melosky B, Shih J-Y, Jialei Wang, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan J-L, Salinas J, Tomasini P, **Gentzler RD**, William WN, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study. *Annals of Oncology*, 2024: 35(1):77-90
4. **Gentzler RD\***, Villaruz LC, Rhee JC, Horton B, Mock J, Hanley M, Kim K, Rudek MA, Phelps MA, Carducci MA, Piekarz R, Park K, Bullock TN, Rudin CM. Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in previously untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. *The Oncologist*, 2023: 28(11):1007-e1107.
5. **Gentzler RD\***, Mohindra NA, Jalal SI, Reckamp KL, Hall RD, Hanna NH, Chae Y, Koczywas M, Helenowski IB, Patel JD. Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175. *The Oncologist*, 2024: *The Oncologist*, 2024:29(1):47-56
6. Fadul CE\*, Sarai G, Bovi JA, Thomas AA, Novicoff W, Anderson R, Amidon RF, Schuetz S, Singh R, Chang A, **Gentzler RD**, Gaughan EM, Sheehan JP. Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases. *Cancers*, 2023; 15(12):3255.
7. Wei CX, Mamdani H, **Gentzler R**, Kalra M, Perkins S, Althouse S, Jalal SI\*. A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. *Clinical Lung Cancer*, 2023;24(4):347-352.
8. Shantzer LB, Dougherty SC, Bolte F, Melson JW, Reed DR, Lynch AC, **Gentzler RD**, Novicoff W, Hall RD\*. Immune-related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination with Chemotherapy: A Brief Report. *Clinical Lung Cancer*, 2023;24(2):e60-e64.
9. Morris BB, Smith JP, Zhang Q, Jiang Z, Hapton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silv AS, Villano JL, vogelbaum MA, Borges VF, Akerley WL, **Gentzler RD**, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA,

- Larner JM, Stukenberg PT, Jones DR, Mayo MW\*. Replicative Instability Drives Cancer Progression. *Biomolecules*, 2022;12(11):1570.
10. Bolte FJ, McTavish S, Wakefield N, Shantzer L, Hubbard C, Krishnaraj A, Novicoff W, **Gentzler RD**, Hall RD\*. Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. *Frontiers in Oncology*, 2022;12:986236.
  11. Ardeshir-Larijani F, Althouse SK, Leal T, Feldman LE, Hejleh TA, Patel M, **Gentzler RD**, Miller AR, Hanna NH\*. A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. *Clinical Lung Cancer*, 2022;23(7):578-584.
  12. Schoenfeld JD\*, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, **Gentzler RD**, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazez AM, Hodi FS. Durvalumab Plus Tremelimumab Alone or in Combination with Low-dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial. *Lancet Oncology*, 2022;23(2):279-291.
  13. Horton BJ\*, Wages NA, **Gentzler RD**. Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. *International Journal of Environmental Research and Public Health*, 2021; 18(21):11452.
  14. Riely GJ\*, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Taso A, Patel JD, Gadgeel S, Bazhenova L, Zhu VW, West H, Mekhail T, **Gentzler RD**, Nguyen D, Bunn V, Jin S, Feng Z, Janne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. *Cancer Discovery*, 2021;11(7):1688-1699.
  15. Monjazez AA, Giobbie-Hurder A, Lako A, Thrash EM, Brennick R, Kao KZ, Manuszak C, **Gentzler RD**, Tesfaye A, Jabbour S, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon H, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina A, Merleev A, Severgnini M, Pfaff K, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig S, Hodi FS, Schoenfeld JD\*. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, 2021;27(9):2470-2480.
  16. Morris BB, Wages NA, Grant PA, Stukenberg PT, **Gentzler RD**, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo MW\*. MYBL2-Driven Transcriptional Programs Link Replication Stress and

Error-prone DNA Repair with Genomic Instability in Lung Adenocarcinoma. *Front Oncol.* 2021;10:585551.

17. Bertino EM<sup>†</sup>, **Gentzler RD**<sup>†</sup>, Clifford SE, Kolesar JM, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann CL, Malhotra J, Villaruz LC, Paweletz CP, Lau CJ, Sholl LM, Takebe N, Moscow JA, Shapiro GI, Janne PA\*, Oxnard GR. Phase IB study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). *Clinical Cancer Research.* 2021;27(6):1604-1611.  
† Dr. Bertino and Dr. Gentzler are co-first authors and contributed equally.
18. Hollen PJ, Gralla RJ\*, **Gentzler RD**, Hall RD, Coyne B, Cheng H, Halmos B, Gildersleeve J, Calderon C, Hinton I, Weiss G, Crawford J, Cerise J, Lesser M. Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. *Oncologist.* 2021;26(3):224-230.
19. Awad MM\*, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Brief Report: Long-Term Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Journal of Thoracic Oncology* 16(1):162-168, 2021.
20. Arora P, Talamo L, Dillon P, **Gentzler RD**, Millard T, Salerno M, Slingluff CL Jr, Gaughan EM\*. Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. *Cardiooncology* 6:21, 2020.
21. Dutta SW\*, Mack ML, Aliotta E, Ward KA, Muller DA, Lerner JM, Fadul CE, Hall RD, **Gentzler RD**, Sheehan JP. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases. *Journal of NeuroOncology* 149(2):357-366, 2020.
22. **Gentzler RD\***, Riley DO, Martin LM. Striving toward improved outcomes for surgically-resectable non-small cell lung cancer: the promise and challenges of neoadjuvant immunotherapy. *Current Oncology Reports*, 15;22(11), 2020.
23. Silvestre J, Gosse T, Read P, **Gentzler R**, Purow B, Asthagiri A, Gaughan E, Dillon PM, Lerner JM, Anderson RT, Sheehan JP, Fadul CE\*. Genesis of Quality Measurements to Improve the Care Delivered to Patients with Brain Metastases. *JCO Oncology Practice.* 2021;7(3):e397-e405.
24. Durm G\*, Althouse S, Sadiq A, Jalal SI, Jabbour S, Zon R, Kloecker GH, Williamson M, Reckamp KL, Kio E, Langdon R, Adesunloye B, **Gentzler RD**, Harb W, Walling R, Yeon C, Koczywas M, Hanna N. A Phase II Trial of Consolidation Pembrolizumab Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Cancer Research Network (HCRN) LUN 14-179. *Cancer*, 126(19):4353-4361, 2020.

25. McLoughlin EM, **Gentzler RD\***. Epidermal Growth Factor Receptor Mutations. *Thoracic Surgery Clinics* 30(2):127-136, 2020
26. McLoughlin EM, Fadul CE, Patel SH, Hall RD, **Gentzler RD\***. Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a patient with BRAF V600E-mutated Lung Adenocarcinoma. *Journal of Thoracic Oncology* 14(12):e269-271, 2019.
27. McLoughlin EM, Lerner JM, Bergman MP, Stelow EB, Brady K, Lynch AC, Abraham RS, **Gentzler RD\***. Rapid Response to Pembrolizumab in a Critically-Ill Mechanically Ventilated Patient with New Diagnosis of Non-Small Cell Lung Cancer (NSCLC). *Journal of Thoracic Oncology* 14(9):e193-e195, 2019.
28. Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L, Mohammed N, **Gentzler RD**, Lerner J, Fadul CE, Sheehan JP. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. *Journal of Neurosurgery* 26:1-8, 2019.
29. Reed DR\*, Hall RD, **Gentzler RD**, Volodin L, Douvas MG, Portell CA. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. *Clinical Lymphoma Myeloma Leukemia*, 19(6):e247-e250, 2019.
30. Paudel N, Schulze D, **Gentzler RD**, Evens AM, Helenowski I, Dillehay G, Frankfurt O, Mehta J, Donnelly ED, Gordon LI, Winter JN, Mittal BB\*. Patterns of Failure and Survival Outcomes After Total Lymphoid Irradiation and High-Dose Chemotherapy With Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. *International Journal of Radiation Oncology, Biology, Physics* 104(2):436-446, 2019.
31. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* 14(1):124-129, 2019.
32. Zaemes J, Hall RD, **Gentzler RD\***. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient with Dual G719S and S768I EGFR Mutations. *Journal Thoracic Oncology* 13(8):e136-e137, 2018.
33. Volaric A, **Gentzler R**, Hall R, Mehaffey JH, Stelow EB, Bullock TN, Martin LW, Mills AM\*. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed with PD-L1. *American Journal of Surgical Pathology* 42(9):1216-1223, 2018.
34. Recio-Boiles A, Galeas JN, Goldwasser B, Sanchez K, Man LM, **Gentzler RD**, Gildersleeve J, Hollen PJ, Gralla RJ. Enhancing Evaluation of Sarcopenia in Patients with Non-Small Cell Lung Cancer (NSCLC) by Assessing Skeletal

Muscle Index (SMI) at the First Lumbar (L1) Level on Routine Chest Computed Tomography (CT). *Supportive Care in Cancer* 26(7):2353-2359, 2018.

35. Chae YK\*, Chiec L, Mohindra N, **Gentzler R**, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. *Cancer Immunology Immunotherapy* 66(1):25-32, 2017.
36. Langer CJ\*, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncology* 17(11):1497-1508, 2016.
37. Karlin J, **Gentzler R**, Golen J\*. Bilateral anterior uveitis associated with nivolumab therapy. *Ocular Immunology and Inflammation* 6:1-3, 2016.
38. **Gentzler R**, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE\*. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. *Immunotherapy* 8(5):583-600, 2016.
39. Hall RD, Le TM, Haggstrom DA, **Gentzler RD\***. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). *Translational Lung Cancer Research* 4(5):515-523, 2015.
40. **Gentzler RD**, Johnson ML\*. Complex decisions for the first-line treatment of advanced wild-type NSCLC. *The Oncologist* 20(3):299-306, 2015.
41. **Gentzler RD\***, Yentz SE, Johnson ML, Rademaker AW, Patel JD. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. *Cancer* 120(24):3853-8, 2015.
42. Gao J\*, **Gentzler RD**, Timms AE, Horwitz MS, Frankfurt O, Altman JK, Peterson LC. Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. *Journal of Hematology and Oncology* 7(1):36, 2014.
43. **Gentzler RD**, Patel JD\*. Optimal first-line and maintenance therapies for advanced non-squamous NSCLC. *Journal of the National Comprehensive Cancer Network* 12(6):889-97, 2014.
44. **Gentzler RD**, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN\*. F-18 FDG-PET Predicts Outcomes for Patients Receiving Total Lymphoid Irradiation and Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. *British Journal of Haematology*. 165(6):793-800, 2014.

45. **Gentzler RD**, Patel JD\*. Maintenance treatment after induction therapy in NSCLC: latest evidence and clinical implications. *Therapeutic Advances in Medical Oncology*. 6(1):4–15, 2014.
46. **Gentzler RD**, Yentz SE, Patel JD\*. Bevacizumab in Advanced NSCLC: Chemotherapy Partners and Duration of Use. *Current Treatment Options in Oncology* 14:595–609, 2013.
47. Johnson ML\*, **Gentzler RD**, Yu HA, Riely GJ. Resistance to targeted molecular therapies in non-small cell lung cancer. *Personalized Medicine in Oncology*. 2(1):24–33, 2013.
48. **Gentzler RD**, Minella AC, Stein BL\*. Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: a case of imatinib-responsiveness. *Leukemia Research Reports* 1(1):9–12, 2012.
49. **Gentzler RD**, Altman JK, Plataniias LC\*. An overview of the mTOR pathway as a target in cancer therapy. *Expert Opinion on Therapeutic Targets* 16(5):481–489, 2012.
50. **Gentzler RD\***. A case of acute spontaneous tumor lysis syndrome and new diagnosis of Burkitt's lymphoma. *The Medicine Forum*. 2009;11:21–22. (Electronic publication: <http://jdc.jefferson.edu/tmf/vol11/iss1/10>)
51. **Gentzler RD\***, Kahn DA. Histiocytic sarcoma: A case of a 52-year-old female with two synchronous primary malignancies at presentation. *The Medicine Forum*. 2009;11:31–33. (Electronic publication: <http://jdc.jefferson.edu/tmf/vol11/iss1/15>)

\*Corresponding author

## B. Books and/or Chapters

1. **Gentzler RD**, Martin L. Screening, Staging, and Stage I Non-Small Cell Lung Cancer. In: Abutalib SA, Benson AB, Markman M, eds. *Cancer Consult: Expertise for Clinical Practice*, 2nd Edition. New York: John Wiley & Sons, Inc, 2023. Available: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781119823766>
2. Baglione AN, Tolman S, Dapaah C, Johnson D, Wells KJ, Hall RD, **Gentzler RD**, Barnes LE. mHealth for Medication and Side Effect Monitoring: Patients' Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment. In: Tsanas, A., Triantafyllidis, A., eds. *Pervasive Computing Technologies for Healthcare*. PH 2022. Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, vol 488. Springer, Cham, Switzerland, 2023.
3. Filicko-O'Hara J, **Gentzler R**, Krause J. Multiple myeloma and acquired von Willebrand disease. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*, 2nd Edition. Chicago: ASCP Press, 2019.

4. Filicko-O'Hara J, **Gentzler R**, Krause J. Light chain deposition disease. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*, 2nd Edition. Chicago: ASCP Press, 2019.
5. Filicko-O'Hara J, **Gentzler R**, Gulati G. Multiple myeloma. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*, 2nd Edition. Chicago: ASCP Press; 2019.
6. Filicko-O'Hara J, **Gentzler R**, Gulati G. Monoclonal Gammopathy of Undetermined Significance. In: Gulati G, Filicko-O'Hara J, Krause J, eds. *Case Studies in Hematology and Coagulation*, 2nd Edition. Chicago: ASCP Press; 2019.
7. Filicko-O'Hara J, **Gentzler R**, Gulati G. Amyloidosis. In: Gulati G, Filicko-O'Hara J, Krause J, eds. *Case Studies in Hematology and Coagulation*, 2nd Edition. Chicago: ASCP Press; 2019.
8. Patel JD, **Gentzler RD**. Lung Cancer, Small-Cell. ACP Smart Medicine (on-line). American College of Physicians. 2014. Available: [smartmedicine.acponline.org](http://smartmedicine.acponline.org). August 2014.
9. Filicko-O'Hara J, **Gentzler R**, Krause J. Multiple myeloma and acquired von Willebrand disease. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*. Chicago: ASCP Press, 2012:297–299.
10. Filicko-O'Hara J, **Gentzler R**, Krause J. Light chain deposition disease. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*. Chicago: ASCP Press, 2012:294–296.
11. Filicko-O'Hara J, **Gentzler R**, Gulati G. Multiple myeloma. In: Gulati, G, Filicko-O'Hara, J, Krause, J, eds. *Case Studies in Hematology and Coagulation*. Chicago: ASCP Press; 2012:284–285.
12. Filicko-O'Hara J, **Gentzler R**, Gulati G. Monoclonal Gammopathy of Undetermined Significance. In: Gulati G, Filicko-O'Hara J, Krause J, eds. *Case Studies in Hematology and Coagulation*. Chicago: ASCP Press; 2012:280–281.
13. Filicko-O'Hara J, **Gentzler R**, Gulati G. Amyloidosis. In: Gulati G, Filicko-O'Hara J, Krause J, eds. *Case Studies in Hematology and Coagulation*. Chicago: ASCP Press; 2012:284–285.

### C. Health Ed., Videos, etc.

1. **Gentzler RD** and Aggarwal C. What to know about treatment options before and after surgery for early-stage non-small cell lung cancer. *ASCO Cancer.net Podcasts*. Cancer.net. November 7, 2023. Available: <https://www.cancer.net/blog/2023-11/what-know-about-treatment-options-and-after-surgery-early-stage-non-small-cell-lung-cancer>

2. **Gentzler RD**, Reiss J. Managing EGFR-Mutated Non-Small Cell Lung Cancer in Today's Clinic: Expert Answers to Frequently Asked Questions. *Expert Think Tank: Resources to Improve the Care of Patients with NSCLC and EGFR Mutations*. Clinical Care Options. September 28, 2022. Available: <https://www.clinicaloptions.com/oncology/programs/2021/egfr-nsclc-think-tank/podcast/podcast>
3. **Gentzler RD**. Cost and Financial Hardship Abstracts from ASCO 2022. *ASCO Meeting Abstracts Tweeetorial*. Twitter.com. June 29, 2022. Available: <https://twitter.com/ryangentzler/status/1542271827820658689?s=20&t=o6EHOV-AJoAOcWU6k6M8nQw>
4. **Gentzler RD**. Global Health Abstracts from ASCO 2022. *ASCO Meeting Abstracts Tweeetorial*. Twitter.com. June 23, 2022. Available: <https://twitter.com/ryangentzler/status/1540111449925849090?s=20&t=o6EHOV-AJoAOcWU6k6M8nQw>
5. **Gentzler RD**, Le X, Stiles B, Velcheti V. Molecular Testing for Early-Stage Non-Small Cell Lung Cancer. *ASCO Cancer.net Podcasts*. Cancer.net. June 15, 2022. Available: <https://www.cancer.net/blog/podcasts/molecular-testing-early-stage-non-small-cell-lung-cancer-with-ryan-gentzler-md-xiuning-le-md-phd>
6. **Gentzler RD**. Adjuvant Immunotherapy for Early-Stage Non-Small-Cell Lung Cancer. *ASCO Education: Expert Answers*. September 7, 2021. Available: <https://education.asco.org/product-details/adjuvant-therapy-for-early-stage-lung-cancer>

#### D. Short Communications

1. **Gentzler RD**. Vital Signs: What you need to know about lung cancer. *The Daily Progress*, Charlottesville, VA, November 7, 2023. Available: [https://dailyprogress.com/life-entertainment/local/wellness/vital-signs-what-you-need-to-know-about-lung-cancer/article\\_43220ab6-78d5-11ee-b894-cfbf8ed9ade6.html](https://dailyprogress.com/life-entertainment/local/wellness/vital-signs-what-you-need-to-know-about-lung-cancer/article_43220ab6-78d5-11ee-b894-cfbf8ed9ade6.html)
2. **Gentzler RD**, Hall RD. Checkpoint Inhibitors in Operable NSCLC: New Adjuvant and Neoadjuvant Approaches to Treatment Are Improving Outcomes. *Clinical Oncology Update*, Volume 1, NEJM Group, a division of the Massachusetts Medical Society, Waltham, MA. June 2023.
3. **Gentzler RD**, Hall RD. Vital Signs: The importance of screening for lung cancer. *The Daily Progress*, 06 November, 2022. Available: [https://dailyprogress.com/lifestyles/health-med-fit/vital-signs-the-importance-of-screening-for-lung-cancer/article\\_810ae112-5bdb-11ed-9bb2-e387b7e71942.html](https://dailyprogress.com/lifestyles/health-med-fit/vital-signs-the-importance-of-screening-for-lung-cancer/article_810ae112-5bdb-11ed-9bb2-e387b7e71942.html)

#### E. Abstracts



1. Maheshwari S, Smilnak G, Singh R, Williams E, Stelow E, Pandey S, Martin L, Larner J, Hall R, **Gentzler R**. Next-generation sequencing (NGS) completion and timeliness using reflex testing protocol for patients with stage II-III non-squamous non-small cell lung cancer (NS-NSCLC). *ASCO Annual Meeting*, May 31-June 4, 2024. Chicago, IL. Abstract: 8060 (Poster)
2. Sharp J, Young P, Zhao S, Patel S, Wei L, Li M, Brownstein J, Haglund K, Palmer J, Raval R, Shields P, He K, Kaufman J, Memmott R, Alahmadi A, Carbone D, Otterson G, Presley C, **Gentzler R**, Owen D. A multi-center cohort study Examining risk factors for central nervous system metastases (CNSm) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation (ChemoRT) followed by durvalumab (Durva). *ASCO Annual Meeting*, May 31-June 4, 2024. Abstract: 8076 (Poster)
3. Iams W, Mitra A, Guittar J, **Gentzler R**, Schwind R, Dugan A, Liu Y, Won Hyun S, Stein M, Sasser K, Ben-Shachar R, Nimeiri H, Patel J, Chaudhuri A. Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy. *ASCO Annual Meeting*, May 31-June 4, 2024. Abstract: 3046 (Poster)
4. Owonikoko T, Chiappori A, **Gentzler R**, Liu S, Onitilo A, Pennell N, Sands J, Wang B, Lowenthal B, Bebchuk J, Eli L, Wong E, Dowlati A. Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study. *ASCO Annual Meeting*, May 31-June 4, 2024. Chicago, IL Abstract: TPS8128 (Poster)
5. Mamdani H, Kim S, **Gentzler R**, Shields M, Furqan M, Pizana K, Abid Q, Jalal S. A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study. *ASCO Annual Meeting*, May 31-June 4, 2024. Abstract: TPS8129 (Poster)
6. **Gentzler RD\***, Spira AI, Melosky B, Owen S, Burns TF, Massarelli E, Nagasaka M, Fang B, Sanborn RE, Arrieta O, Card C, Cappuzzo F, Xia K, Chu Pei-Ling, Shah S, Dioro B, Girvin A, Mahadevia P, Bauml JM, Reckamp KL. Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2. European Lung Cancer Congress (ELCC) 2024, March 20-23, 2024. Prague, Czech Republic. Abst: 3MO (mini oral).
7. Young P, Sharp J, Michaels K, Fultineer K, Hall R, Lynch A, Thomas M, Owen D, **Gentzler R**. Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study. *IASLC North American Conference on Lung Cancer 2023*, December 1-3, 2023. Chicago, IL. Abst: PP01.135.
8. Passaro A\*, Cho BC, Wang Y, Melosky B, Califano R, Lee S-H, Girard N, Reckamp KL, Takahashi T, Felip E, **Gentzler RD**, Popat S, Nassib William W, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Garcia-Campelo MR, Wang

- J. Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after disease progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. *ESMO Congress 2023*, October 20-24, 2023. Madrid, Spain. Abst LBA15 (Presidential Oral)
9. **Gentzler RD\***, Sharma N, Mitra A, Ben-Shachar R, Stein MM, Guinney J, Nimeiri H, Iams W, Aggarwal C, Patel J. Genomic characterization of sporadic *MET* amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes. *ESMO Congress 2023*, October 20-24, 2023. Madrid, Spain. Abst 203P (Poster)
  10. Patel J\*, Ben-Shachar R, Nadhamuni K, Carty M, Pelosof R, Klein I, Nimeiri H, Aggarwal C, **Gentzler RD**. Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with fusion-positive NSCLC. *ESMO Congress 2023*, October 20-24, 2023. Madrid, Spain. Abst 185P (Poster)
  11. Iams W\*, Ben-Shachar R, Gai L, Beauchamp K, Sharma N, Islam S, Guinney J, Nimeiri H, **Gentzler RD**, Cohen E. ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset. *ESMO Congress 2023*, October 20-24, 2023. Madrid, Spain. Abst 182P (Poster)
  12. Piotrowska Z\*, Chen LN, Shum E, Park C, Guo M, Liu Y, Tran M, Marks JA, Banwait M, Liu SV, Scott SC, Bestvina CM, Riess JW, Marrone KA, Hall RD, **Gentzler RD**, Shu CA. Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort. *ASCO Annual Meeting*, June 2-6, 2023. Chicago, IL. Abst: 9108 (Poster)
  13. **Gentzler R\***, Mohindra N, Jalal S, Reckamp K, Hall R, Hanna N, Chae Y, Koczywas M, Helenowski I, Patel J. Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175. *IASLC 2022 North America Conference on Lung Cancer*, September 23-25. Chicago, IL. Abst: PP01.44 (Poster)
  14. **Gentzler RD**, Piekarcz R, Villaruz LC, Rhee JC, Wei-Chu VL, Horton B, Mock J, Hanley M, Rudek MA, Phelps MA, Carducci MA, Rudin CM. Phase I study of entinostat (Ent), Atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399. *ASCO Annual Meeting*, June 4-7, 2022. Chicago, IL. Abst:e20606 (Publication)
  15. Neal JW\*, Santoro A, Viteri S, Aix SP, Fang B, Lim FL, **Gentzler RD**, Goldschmidt JH, Khizman P, Massarelli E, Patel SB, Puri S, Sudhagoni R, Scheffold C, Curran D, Felipe E. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. *ASCO Annual Meeting*, June 4-7, 2022. Chicago, IL. Abst:9005 (Oral Abstract)
  16. Shantzer L\*, Dougherty SC, Novicoff W, Melson JW, Reed DR, Lynch AC, **Gentzler RD**, Hall RD. Immune-related adverse events correlate with improved

- outcomes in patients with advanced non-small cell lung cancer treated with combinations of immune-checkpoint inhibitors and chemotherapy. *SITC 2021*; November 10-14, 2021; Washington, DC. Abst:803 (Poster)
17. Spira AI\*, Ramalingam SS, Neal JW, Piotrowska Z, Mekhail T, Tsao A, **Gentzler RD**, Riely GJ, Bazhenova L, Gadgeel S, Nguyen D, Johnson ML, Jin S, Griffin C, Bunn V, Lin J, Churchill EN, Mehta M, Janne PA. Mobocertinib in EGFR exon 20 insertion–positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. *IASLC 2021 World Conference on Lung Cancer*; September 8-14, 2021; Denver, CO. Abst:OA15.01, (Oral Abstract)
  18. Riley DO\*, Kaur N, Baglione AN, Hall RD, Barnes LE, **Gentzler RD**. Adverse event burden of oral tyrosine kinase inhibitors in EGFR and ALK metastatic non-small cell lung cancer. *IASLC 2021 World Conference on Lung Cancer*; September 8-14, 2021; Denver, CO. Abst:P45.16, (Poster)
  19. Riley DO\*, Abraham RS, Alaklabi SF, Devitt ME, Hall RD, Horton BJ, **Gentzler RD**. CNS adverse events and survival in patients with NSCLC brain metastases treated with concurrent radiation and immunotherapy. *IASLC 2021 World Conference on Lung Cancer*; September 8-14, 2021; Denver, CO. Abst: P40.04, (Poster)
  20. Ardeshir-Larijani F\*, Althouse SK, Leal T, Feldman LE, Hejleh TA, Patel M, **Gentzler RD**, Miller AR, Hanna NH. Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139. *ASCO Annual Meeting 2021*; June 3-8, 2021; Virtual. Abst: 9034. (Poster)
  21. Moore ME\*, Mills AM, **Gentzler RD**, Hall RD, Melson JW, Stelow EB. Examination of PD-L1 and MHC Class I Expression in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy. *USCAP 2021 Annual Meeting*; March 13-18, 2021; Virtual. Abst: 941 (Poster)
  22. Neal JW\*, Lim FH, Filip E, **Gentzler R**, Patel S, Baranda J, Fang B, Squillante C, Simonelli M, Werneke S, Curran D, Aix SP. Cabozantinib in combination with atezolizumab in NSCLC patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study. *IASLC World Conference on Lung Cancer 2020*; January 28-31,2021; Singapore (Virtual). Abst: FP14.08. (Poster)
  23. Mock J\*, Wynter E, Young P, Sytov A, Elghawy O, Novicoff W, **Gentzler R**, Hall R. Association of Opioid Use with Survival in Non-Small Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy. *IASLC North America Conference on Lung Cancer*; October 16-17, 2020; Worldwide (Virtual). Abst: MO01.12, (Poster)
  24. Awad MM\*, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. KEYNOTE-021 cohort G long-term follow-up: first-line (1L) pemetrexed and carboplatin (PC) with or

- without pembrolizumab for advanced nonsquamous NSCLC. *IASLC North America Conference on Lung Cancer*; October 16-17, 2020; Worldwide (Virtual). Abst:OFP01.02, (Oral Poster Presentation)
25. Riely GJ\*, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Taso A, Patel JD, Gadgeel S, Bazhenova L, Zhu VW, West H, Mekhail T, **Gentzler R**, Nguyen D, Bunn V, Jin S, Feng Z, Janne PA. Updated results from a phase 1/2 study of mobocertinib (TAK-788) in NSCLC with *EGFR* exon 20 insertions (exon20ins). *European Society of Medical Oncology (ESMO) Congress*. September 19-21, 2020; Madrid, Spain (virtual). Abst: 1261MO, (Mini Oral Abstract).
26. Dutta S\*, Mack M, Ward K, Aliotta E, Hall R, **Gentzler R**, Sheehan J. Outcomes based on brain metastases characteristics and treatment modality for patients with *EGFR*-mutated and *ALK*-rearranged non-small cell lung cancer (NSCLC). 2020. *ASTRO Annual Meeting*; October 24-28, 2020; Miami Beach, FL. Abst:3602 (Poster)
27. Liu SV\*, Hall RD, Saltos AN, Otterson GA, Tan MT, Gnjatic S, **Gentzler RD**, Tanvetyanon T, Chen HX, Sharon E. A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166. *2020 ASCO Annual Meeting*; May 29-31, 2020; Chicago, IL (virtual). Abst: TPS9638. (Poster)
28. Neal JW\*, Lim FL, Filip E, **Gentzler RD**, Patel SB, Baranda J, Fang B, Squillante CM, Simonelli M, Werneke S, Curran D, Aix SP. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. *2020 ASCO Annual Meeting*; May 29-31, 2020; Chicago, IL (virtual). Abst:9610 (Poster)
29. Shukla N\*, Althouse SK, Sadiq AA, Jalal SI, Jabbour SK, Zon R, Kloecker GH, Fisher WB, Reckamp KL, Kio EA, Langon RM, Adesunloye B, **Gentzler RD**, Hanna NH, Durm GA. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179. *2020 ASCO Annual Meeting*; May 29-31, 2020; Chicago, IL (virtual). Abst:9032. (Poster)
30. **Gentzler RD\***, Mohindra N, Jalal S, Reckamp K, Hall R, Hanna N, Chae YK, Villafior V, Koczywas M, Helenowski I, Rademaker A, Patel J. Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose. *IASLC 2019 World Conference on Lung Cancer*; September 8, 2019; Barcelona, Spain. Abst: P1.01-67 (Poster)
31. Langer CJ\*, Gadgeel SM, Borghaei H, Patnaik A, Powell SF, **Gentzler RD**, Yang JC, Gubens M, Sequist LV, Awad MM, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, Lunceford J, Ayers M, Lubiniecki GM, Piperdi B, Pietanza MC, Papadimitrakopoulou VA. KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC. *IASLC 2019 World Conference on Lung Cancer*; September 8, 2019; Barcelona, Spain. Abst:OA04.05 (Oral Abstract)

32. Durm G\*, Althouse S, Sadiq A, Jalal SI, Jabbour S, Zon R, Kloecker GH, Williamson M, Reckamp KL, Kio E, Langdon R, Adesunloye B, **Gentzler RD**, Harb W, Walling R, Yeon C, Koczywas M, Hanna N. ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. *IASLC 2019 World Conference on Lung Cancer*; September 8, 2019; Barcelona, Spain. Abst: P1.18-05 (Poster).
33. Moore M, Hall R\*, McLoughlin E, Melson J, Horton B, Mills A, **Gentzler R**. Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI). *IASLC 2019 World Conference on Lung Cancer*; September 8, 2019; Barcelona, Spain. Abst: P2.04-75 (Poster)
34. McLoughlin E\*, Hanson L, Moore M, Horton B, **Gentzler R**, Hall R. Clinical Characteristics and Outcomes in NSCL Patients Associated with Very High PD-L1 Expression. *IASLC 2019 World Conference on Lung Cancer*; September 8, 2019; Barcelona, Spain. Abst: P2.01-52 (Poster)
35. Melson J, Reed D, Horton BJ, Moore M, Brown JT, **Gentzler RD**, Hall RD\*. Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy. *ASCO-SITC Clinical Immuno-Oncology Symposium*; February 28, 2019; San Francisco, CA. Abst:83 (Poster)
36. Monjazebe A\*, Giobbie-Hurder A, Lako A, Tesfaye AA, Stroiney AS, **Gentzler RD**, Jabbour S, Alese OB, Rahma OE, Cleary JM, Sharon E, Raben D, Mamon HJ, Streicher H, Chen HX, Ahmed M, Gjini E, Rodig S, Hodi FS, Schoenfeld JD. Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation. *ASCO-SITC Clinical Immuno-Oncology Symposium*; February 28, 2019; San Francisco, CA. abst: 49. (Poster)
37. Durm G\*, Althouse S, Sadiq A, Jalal S, Jabbour S, Zon R, Kloecker GH, Fisher W, Reckamp KL, Kio E, Langdon R, Adesunloye B, **Gentzler R**, Hanna N. Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC. *IASLC World Conference on Lung Cancer*; September 23-26, 2018; Toronto, Canada. abst: OA01.07. (Oral Abstract)
38. Gralla RJ\*, Hollen PJ, Hall R, **Gentzler R**, Cheng H, Halmos B, Crawford J, Cerise J, Lesser M. Can Benefit of Futility in Treating Advanced NSCLC be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO. *IASLC World Conference on Lung Cancer*; September 23-26, 2018; Toronto, Canada. abst: P2.01-39. (Poster)
39. Brown JT\*, Hall RD, **Gentzler RD**, Balkrishnan R, Desai RP, Moore ME, Moore AR, Li LX. Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC. *IASLC World Conference on Lung Cancer*; September 23-26, 2018; Toronto, Canada. Abst: P3.01-09 (Poster)

40. **Gentzler RD\***, Langer CJ, Borghaei H, Gadgeel SM, Papadimitrakopoulou V, Patnaik A, Powell SF, Martins RG, Stevenson J, Jalal SI, Panwalkar AW, Yang JC-H, Gubens MA, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. *ASCO Annual Meeting*; June 1-5, 2018; Chicago, IL. abst: 9026. (Poster)
41. Devitt ME\*, Abraham RS, Hines J, Horton BJ, Fadul CE, Larner JM, Sheehan J, Hall RD, **Gentzler RD**. Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs). *ASCO Annual Meeting*; June 1-5, 2018; Chicago, IL. abst: 2010. (Poster Discussion, Merit Award)
42. Durm GA\*, Althouse SK, Sadiq AA, Jalal SI, Jabbour S, on R, Kloecker GH, Fisher WB, Reckamp KL, Kio EA, Langdon RM, Adesunloye B, **Gentzler RD**, Hanna NH. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. *ASCO Annual Meeting*; June 1-5, 2018; Chicago, IL. Abst 8500. (Oral)
43. Gralla RJ\*, Hollen PJ, Hall RD, **Gentzler RD**, Cheng H, Halmos B, Crawford J, Lesser M. Early determination of benefit or futility in treating NSCLC using the LCSS 3-Item Global Index (3-IGI). *ASCO Annual Meeting*; June 1-5, 2018; Chicago, IL. Abst 9086. (Poster)
44. Volaric A\*, **Gentzler R**, Stelow E, Mills A. Indoleamine-2,3-Dioxygenase (IDO-1) Expression in Non-Small Cell Lung Cancer (NSCLC): A Targetable Mechanism of Immune Resistance and Candidate for Dual Therapy with Anti-PD-1/PD-L1. *USCAP Annual Meeting*; March 17-23, 2018; Vancouver, BC, Canada. (Poster)
45. Devitt, ME, Gade KE\*, Hall RD, Horton BJ, Stelow EB, Bullock T, **Gentzler RD**. The effect of chemotherapy on the tumor immune microenvironment in non-small cell lung cancer (NSCLC): a single-institution retrospective analysis. 2018. *ASCO-SITC Clinical Immuno-Oncology Symposium*, San Francisco, CA. Abst: 155. (Poster, Merit award)
46. Borghaei H\*, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jaal SI, Panwalkar A, Yang JC-H, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Raftopoulos H, Gandhi L. Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC: KEYNOTE-021 Cohort G Update. *IASLC World Conference on Lung Cancer*; October 15-19, 2017; Yokohama, Japan. Abst: OA 17.01. (Oral Presentation)
47. Hollen PJ\*, Gralla RJ, Coyne B, Hall R, **Gentzler R**, Cheng H, Weiss G, Calderon C, Gildersleeve J, Hinton I, Crawford J, Rosen L, Lesser M. Do patients treated with chemotherapy for advanced NSCLC regret having received treatment? A prospective evaluation in 164 patients. *IASLC World Conference on Lung Cancer*; October 15-19, 2017; Yokohama, Japan. Abst: MA 08.11. (Mini Oral Presentation)

48. Gralla RJ\*, Hollen PJ, Gaspé N, Hall R, **Gentzler R**, Cordero H, Cheng H, Calderon C, Gildersleeve J, Crawford J, Rosen L, Lesser M. Reducing hospitalization in patients receiving chemotherapy for NSCLC: predicting risk with the LCSS 3-item Global Index (3-IGI). *IASLC World Conference on Lung Cancer*; October 15-19, 2017; Yokohama, Japan. Abst: P2.01-50. (Poster)
49. Borghaei H\*, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jaal SI, Panwalkar A, Yang JC-H, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Raftopoulos H, Gandhi L. Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. *European Society for Medical Oncology (ESMO) Congress*, September 8-12, 2017; Madrid, Spain. Abst: LBA49. (Oral presentation)
50. Papadimitrakopoulou VA\*, Gadgeel SM, Borghaei H, Gandhi L, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC-H, Gubens M, Sequist LV, Awad MM, Fiore J, Ge YJ, Raftopoulos H, Langer CJ. Updated Results of Keynote-021 Cohort G: First-Line Carboplatin and Pemetrexed (CP) with or without Pembrolizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC). *Asia Pacific Cancer Conference 2017 (APCC 2017)*; June 24, 2017; Seoul, South Korea. (Oral Presentation)
51. Brown JT, Moore Andrew R, Reuss JE, Simon NI, **Gentzler RD**, Hall RD. Implementation of reflexive genomic profiling in non-squamous NSCLC: results of single center experience. *2017 ASCO Annual Meeting*; June 2-6, 2017; Chicago, IL. Abst: e13010. (Publication)
52. Papadimitrakopoulou VA\*, Gadgeel SM, Borghaei H, Gandhi L, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC-H, Gubens M, Sequist LV, Awad MM, Fiore J, Ge YJ, Raftopoulos H, Langer CJ. First-Line Carboplatin and Pemetrexed With or Without Pembrolizumab for Advanced Non-Squamous NSCLC: Updated Results of KEYNOTE-021 Cohort G. *2017 ASCO Annual Meeting*; June 2-6, 2017; Chicago, IL. Abst: 9094. (Poster)
53. Devitt M\*, Hall R, **Gentzler RD**. Peripheral Blood Cell Free DNA to Monitor Mutational Response in EGFR-Mutant Non-Small Cell Lung Cancer. *2017 Multidisciplinary Thoracic Cancers Symposium*; March 2017; San Francisco, CA. Abst: 165 (Poster)
54. **Gentzler RD\***, Mohindra N, Hanna N, Kwang Chae Y, Jalal S, Hall R, Villaflor V, Reckamp K, Koczywas M, Sullivan D, Wood L, Patel J. Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase I Results. *2017 Multidisciplinary Thoracic Cancers Symposium*, March 2017; San Francisco, CA. Abst: 128. (Poster)
55. Tola G, Fitzhugh H, Hall R, Horton B, **Gentzler RD**. Timeliness to treatment in patients with lung cancer at UVA Cancer Center. *ASCO Quality Care Symposium*, Orlando, FL. March 2017. Abst: 169 (Poster)

56. Obeid JM\*, Erdag G, **Gentzler RD**, Brown MG, Cross JV, Deacon DH, Bullock TN, Slingluff CL. Loss of Class I MHC Adds Prognostic Value to PD-L1 Expression in Non-Small Cell Lung Cancer Patients. *12<sup>th</sup> Annual Academic Surgical Congress*; Feb 2017; Las Vegas, NV. Abst: 04.03. (Poster)
57. Langer, CJ\*, Gadgeel S, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge YJ, Raftopoulos H, Gandhi L. Pembrolizumab + Carboplatin and Pemetrexed as 1<sup>st</sup>-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE 021 Cohort G. *IASLC World Conference on Lung Cancer*; December 6, 2016; Vienna, Austria. Abst: MA09.02 (Oral Presentation)
58. Langer, CJ\*, Gadgeel S, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, **Gentzler RD**, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge YJ, Raftopoulos H, Gandhi L. Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: Keynote-021 cohort G. *ESMO 2016 Congress*; October 9, 2016; Copenhagen, Denmark. Abst: LBA46 (Oral Presentation, Presidential Symposium)
59. Aggarwal S, Karlin JN\*, **Gentzler R**, Golen J. Bilateral Anterior Uveitis as Complication of Programmed Death-Ligand Inhibitor Chemotherapeutic Agents. *Ocular Microbiology and Immunology Group (OMIG) Annual Meeting*; October 14, 2016; Chicago, IL. abst:17 (Oral Presentation).
60. **Gentzler RD\***, Boiles AR, Galeas JN, Man LM, Hall RD, Hollen P, Gralla RJ. Prospective evaluation of changes in cancer cachexia in NSCLC in patients given chemotherapy by correlating skeletal muscle mass with PRO Results. *IASLC World Conference on Lung Cancer Abstracts*. September 6-9, 2015; Denver, CO. abst: P3.01-040 (Poster)
61. Galeas JN\*, Boiles AR, Man LM, **Gentzler RD**, Hollen P, Gralla RJ. Enhancing Evaluation of Cancer Cachexia in Patients with NSCLC by Assessing Change in Skeletal Muscle Mass at the L1 Level on Routine Chest CT. *IASLC World Conference on Lung Cancer Abstracts*. September 6-9, 2015; Denver, CO. abst:P1.11-005 (Poster)
62. Boiles AR\*, Galeas JN, Goldwasser B, Sanchez K, Mesias J, Gordon D, Hall RD, **Gentzler RD**, Man LM, Hollen PJ, Gralla RJ. Establishing valid functional / PRO measures in cancer cachexia or sarcopenia to correlate with changes in Skeletal Muscle Mass Index (SMI): Results of a prospective study in patients with non-small cell lung cancer. *ASCO Annual Meeting*; May 29-Jun 2, 2015; Chicago, IL. Abst:e20676 (Publication)
63. **Gentzler RD\***, Yentz SE, Rademaker A, Johnson ML, Patel JD. Review of 10 Years of ASCO Abstracts for Non-Small Cell Lung Cancer (NSCLC) and the Impact of Molecular Biomarkers (MB) in Clinical Trial Selection Criteria. *IASLC World Conference on Lung Cancer*; October 27-30, 2013; Sydney, Australia. Abst:P2.11-006. (Poster Presentation)



64. **Gentzler RD**, Kaklamani VG, Worden R, Zumdahl T, Simm HD, Rademaker A, Johnson ML, Patel JD. Phase (Ph) I study of pazopanib (P) in combination with vinorelbine (V) in patients with metastatic non-small cell lung cancer (mNSCLC) and breast cancer (mBC). *ASCO Annual Meeting*; May 31-Jun 4, 2013; Chicago, IL. Abst:e13568. (Publication)
65. **Gentzler RD\***, Evens AM, Rademaker AW, Mittal BB, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Green JR, Williams S, Kaminer L, Gordon LI, Winter JN. Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. *ASH Annual Meeting Abstracts*. 2012; Atlanta, GA. Abst: 2024 (Poster)
66. **Gentzler RD**, Kraft WK, Leiby BE, Filicko-O'Hara JE. Comparing prognosis estimates of patients with cancer and their oncologists. *ASCO Annual Meeting*; December 8-12, 2012; Chicago, IL. Abst:e16548 (Publication)

\*Abstract presented

## **XVII. INVITED LECTURES AND SYMPOSIUMS**

<u>IASLC 2024 Targeted Therapies of Lung Cancer Meeting</u> Santa Monica, CA "Therapeutic Approaches to Lineage Transformation and Acquired MET Amplification for EGFR NSCLC"	February 22, 2024
<u>Aptitude Health Lung CORE Meeting</u> New York Cancer & Blood Specialists, Staten Island, NY "CORE (Community Oncology Research Evaluations): Strategic Insights Into EGFR Mutant Late-Stage Non-Small Cell Lung Cancer (NSCLC)"	December 12, 2023
<u>Aptitude Health Lung CORE Meeting</u> Advocate Health, Downers Grove, IL "CORE (Community Oncology Research Evaluations): Strategic Insights Into EGFR Mutant Late-Stage Non-Small Cell Lung Cancer (NSCLC)"	December 12, 2023
<u>Aptitude Health Lung CORE Meeting</u> Jefferson Health, Philadelphia, PA "CORE (Community Oncology Research Evaluations): Strategic Insights Into EGFR Mutant Late-Stage Non-Small Cell Lung Cancer (NSCLC)"	December 6, 2023
<u>IASLC 2023 North America Conference on Lung Cancer</u> Chicago, IL "Reconsidering the Optimal approach to first line EGFR therapy (FLAURA2/Ami/lazer)"	December 2, 2023

Session co-chair: “ES04: Therapeutic Approach for EGFR/HER2 and Fusion Driven Cancers”

Aptitude Health Lung CORE Meeting November 16, 2023  
Tennessee Oncology  
“CORE (Community Oncology Research Evaluations): Strategic Insights Into EGFR Mutant Late-Stage Non-Small Cell Lung Cancer (NSCLC)”

Aptitude Health Lung CORE Meeting November 9, 2023  
Highlands Oncology, Prestonburg, KY  
“CORE (Community Oncology Research Evaluations): Strategic Insights Into EGFR Mutant Late-Stage Non-Small Cell Lung Cancer (NSCLC)”

DC Lung Cancer Conference 2023 October 7, 2023  
Washington, DC  
“Best Practice: Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)”

ASCO Advantage Education Program, Lung Cancer July 18–19, 2023  
ASCO Headquarters, Alexandria, VA  
Panelist, “Perioperative Systemic Therapies in Early-Stage NSCLC”  
Small group breakout leader, sessions 5 and 9  
Panelist, “Determinants of Metastatic Treatment Decisions”

IASLC 2023 Targeted Therapies of Lung Cancer Meeting February 23, 2023  
Santa Monica, CA  
Invited Panelist, “Session 1: Targeted Therapies – EGFR, HER2 and MET”

Radiation Oncology Grand Rounds January 26, 2023  
University of Virginia, Charlottesville, VA  
“Advances in Targeted Therapies and Immunotherapies for Lung Cancer”

Clinical Care Options SCLC Program Series (CME) December 15, 2022  
Helen Nassif Cancer Center, Cedar Rapids, IA  
“Small-Cell Lung Cancer: Applying the Latest Developments in Community Practice”

Clinical Care Options SCLC Program Series (CME) November 3, 2022  
Florida Cancer Specialists, Gainesville, FL  
“Small-Cell Lung Cancer: Applying the Latest Developments in Community Practice”

Clinical Care Options SCLC Program Series (CME) October 26, 2022  
Northeast Louisiana Cancer Institute, Monroe, LA  
“Small-Cell Lung Cancer: Applying the Latest Developments in Community Practice”

<u>Hematology/Oncology Grand Rounds (CME)</u> University of Virginia, Charlottesville, VA “Opportunities in the NCI ETCTN”	October 5, 2022
<u>IASLC 2022 North America Conference On Lung Cancer</u> Chicago, IL “Considerations for Duration and De-escalation of Immunotherapy”	September 25, 2022
<u>Clinical Care Options SCLC Program Series (CME)</u> Kootenai Cancer Center, Post Falls, ID “Small-Cell Lung Cancer: Applying the Latest Developments in Community Practice”	August 11, 2022
<u>Summit on Lung Cancer</u> Kohala Coast, HI “Targeting EGFR and MET in Squamous NSCLC”	July 9, 2022
<u>ASCO Annual Meeting 2022</u> Discussant, Lung Cancer – Local-Regional/Small Cell/Other Chicago, IL “Recurrent Small Cell Lung Cancer: Can We Change the Paradigm?”	June 6, 2022
<u>Clinical Care Options EGFR Mutant Think Tank (CME)</u> Beaumont Rose Cancer Center, Royal Oak, MI “Resources to Improve the Care of Patients with NSCLC and EGFR Mutations”	May 25, 2022
<u>OncoLive Institutional Perspectives on Cancer: Lung Cancer</u> Virtual (University of Virginia) Role: Chair, Speaker “Small Cell Lung Cancer”	April 19, 2022
<u>IASLC 2022 Targeted Therapies of Lung Cancer Meeting</u> Santa Monica, CA (Virtual due to COVID-19 Pandemic) “Lineage Plasticity”	February 15, 2022
<u>American Virtual Conference on Lung Cancer (AVCLC 2021)</u> Virtual, Global audience, mostly international attendees “Role of IO in the Adjuvant Setting”	December 7, 2021
<u>ASCO Direct Highlights (CME)</u> Philadelphia, PA (Virtual due to COVID-19 Pandemic) “Lung Cancer – Metastatic”	July 24, 2021
<u>ETCTN Annual Portfolio Webinar</u> NCI, CTEP “Johns Hopkins Translational Science Team and Consortium: 10166 and 10399”	May 14, 2021

<u>Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy</u> Charlottesville, VA (Virtual due to COVID-19 Pandemic) Roles: Meeting organizer, speaker “Cases and Local Clinical Trials”	April 27, 2021
<u>IASLC 2021 Targeted Therapies of Lung Cancer Meeting</u> Santa Monica, CA (Virtual due to COVID-19 Pandemic) Invited Panelist, “Antibody Drug Conjugates”	February 19, 2021
<u>IASLC North America Conference on Lung Cancer</u> Chicago, IL (Virtual due to COVID-19 Pandemic) “How Common is Small Cell Transformation in Oncogene-driven Lung Cancer Such as EGFR and ALK? How Can It Be Treated?”	October 16, 2020
<u>UVA Medicine Grand Rounds (CME)</u> Charlottesville, VA “Lung Cancer for the Internist”	August 21, 2020
<u>ASCO Direct Highlights (CME)</u> Philadelphia, PA (Virtual due to COVID-19 Pandemic) “Lung Cancer – Metastatic”	July 26, 2020
<u>ASCO Annual Meeting 2020</u> Discussant, Lung Cancer – Non-Small Cell Metastatic Poster Discussion Session Chicago, IL (Virtual due to COVID-19 Pandemic) “Sharpening the Approach on RET and ALK”	May 29, 2020
<u>ASCO Annual Meeting 2020</u> Invited Chair, Lung Cancer - Non-Small Cell Metastatic, Oral Session Cancelled due to virtual meeting format (COVID-19)	May 2020
<u>IASLC 2020 Targeted Therapies of Lung Cancer Meeting</u> Santa Monica, CA “Atezolizumab + Cobimetinib”	February 22, 2020
<u>Raleigh General Hospital Grand Rounds (CME)</u> Beckley, WV “Advancements in First-Line Therapeutics for NSCLC”	November 21, 2019
<u>Southside Regional Medical Center Grand Rounds (CME)</u> Petersburg, VA “Advancements in First-Line Therapeutics for NSCLC”	October 2, 2019
<u>Targeted Oncology</u> Charlottesville, VA “Case-Based Peer Perspectives on Metastatic NSCLC”	April 11, 2019
<u>IASLC 19<sup>th</sup> Lung Cancer Targeted Therapies Meeting</u>	February 23, 2019

Santa Monica, CA "Ponatinib" in session "FGFR/PDGFR/Angiogenesis"	
<u>Hematology &amp; Oncology Grand Rounds (CME)</u> University of Virginia "Moving Forward in Lung Cancer: A Changing Standard of Care,"	October 31, 2018
<u>Targeted Oncology</u> Charlottesville, VA "Case-Based Peer Perspectives on Immunotherapy for NSCLC"	October 11, 2018
<u>ETCTN Annual Meeting (Hopkins LAO)</u> Baltimore, MD "An Overview of UVA Participation in ETCTN Trials"	September 21, 2018
<u>OnLive State of the Science Symposium</u> Charlottesville, VA Co-Chaired Symposium Speaker: "Chemotherapy in the I/O Era"	August 7, 2018
<u>IASLC 18<sup>th</sup> Lung Cancer Targeted Therapies Meeting</u> Santa Monica, CA Session Chair, "EGFR"	February 22, 2018
<u>The 43<sup>rd</sup> Annual Edward W. Hook, Jr., MD Recent Advances in Clinical Medicine (CME)</u> OMNI Hotel, Charlottesville, VA. "Cancer Immunotherapy is Here to Stay: What the Primary Care Physician Needs to Know."	October 26, 2016
<u>Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy (CME)</u> Charlottesville, VA "Immunotherapy for the Treatment of Lung Cancer"	October 14, 2016
<u>American Lung Association Lung Force Expo</u> Richmond, VA "Importance of Clinical Trials in Lung Cancer"	May 20, 2016
<u>Charles Hess Memorial Symposium (CME)</u> OMNI Hotel, Charlottesville, VA "Immunotherapy in Lung Cancer"	October 10, 2015
<u>Hematology &amp; Oncology Grand Rounds (CME)</u> University of Virginia "ASCO Updates"	June 17, 2015
<u>The Virginia Thoracic Forum</u> Richmond, VA "Targeted Therapy for Advanced NSCLC"	November 12, 2014

<u>Staffileno Family Head and Neck Cancer Dental Symposium (CME)</u> Northwestern University, Chicago, IL “Mastering Multidisciplinary Challenges in Head and Neck Cancer”	January 17, 2014
<u>Hematology/Oncology Grand Rounds (CME)</u> Northwestern University, Chicago, IL “PD-1 Inhibition as a First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A New Phase I/II Clinical Trial of Lambrolizumab (MK-3475)”	September 13, 2013
<u>Hematology/Oncology Grand Rounds (CME)</u> Northwestern University, Chicago, IL “Total Lymphoid Irradiation with Autologous Stem-Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates”	November 16, 2012
<u>Hematology/Oncology Grand Rounds (CME)</u> Northwestern University, Chicago, IL “ECOG 5508: Maintenance Chemotherapy for Non-Small Cell Lung Cancer after PointBreak”	November 9, 2012
<u>The Chicago Endocrine Surgery Club Fall Meeting (CME)</u> Northwestern University, Chicago, IL “Evaluation and Management of Recurrent Thyroid Cancer”	September 13, 2012
<u>Medicine Grand Rounds (CME)</u> Thomas Jefferson University Hospital, Philadelphia, PA “Resident Clinicopathological Conference: ‘A 70-year old woman with a chronic cough’”	April 7, 2011
<u>Medicine Grand Rounds (CME)</u> Thomas Jefferson University Hospital, Philadelphia, PA “Residency Duty Hours Reform Committee Presentation”	March 3, 2011